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INTRODUCTION 
Cannabis is one of the most widely used illicit substances in the world. 
“With approximately 200 to 300 million regular users, it occupies fourth place 
in worldwide popularity among psychoactive drugs, after caffeine, nicotine and 
alcohol. The prevalence of lifetime use of cannabis by young adults has 
increased in many developed countries over the past several decades. The ready 
availability of the drug, the increasing social disapproval of cigarette smoking, 
stern drinking laws and perceptions that cannabis is safe or less harmful than 
cigarettes or alcohol may explain these changes”.1 
“Today there is no part of the world that is free from the curse of drug 
trafficking & drug addiction. India too is caught in this vicious circle of drug 
abuse, and the numbers of drug addicts are increasing day by day. As per the 
world health report 2002, tobacco & alcohol use were among the ten leading 
risk factors for the global burden of disease measured in DALYs. Besides 
alcohol & tobacco, cannabis, heroin & Indian produced pharmaceutical drugs 
are the most frequently abused drugs in India. Cannabis products often called 
charas, bhang or Ganja are abused throughout the country because it has 
attained some amount of religious sanctity because of its association with some 
Hindu deities.”2  
Many surveys were conducted since 1970’s at various levels & among 
different populations in India to find the prevalence of psychoactive substance 
abuse. “The national household survey of drug use in the country is the first 
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systematic effort to document the nationwide prevalence of drug use. Alcohol 
(21.4%) was the primary substance used (apart from tobacco) followed by 
cannabis (3.0%) & opioids (0.7%)”3. In the recent years, admission related to 
cannabis has been largely increased in our institution.  
“The increasing use of cannabis has raised a series of complex issues 
about both the health effects of cannabis & the appropriate social response to 
increasing cannabis use. Amongst issues relating to the consequences of 
cannabis use, there have been concerns about the extent to which the use of 
cannabis is associated with increased risks of a range of psychosocial problem. 
Specifically, it has been well documented that those who use cannabis are an at 
risk population for a range of adverse psycho social outcomes that include: 
crime; mental health problem, other forms of illicit drug use; social drop out & 
unemployment “4                   
“It is now established that patients who use illicit drugs & suffer from 
comorbid psychiatric illnesses have worse outcomes than drug users without a 
dual diagnosis. In addition, patients with a psychoactive substance use 
diagnosis usually experience a progression from abuse to dependence. The 
progression is very rapid for cocaine and opiate dependence but it also occurs 
in cannabis & alcohol use.”5 
“In this context, genetic & environmental influences cannot fully 
explain cannabis use severity & progression towards other illicit drugs. Indeed 
one other important issue is the ease of access to cannabis already at a young 
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age, which may favor a reduced perception of the risk connected with drug 
abuse as well as compromised judgment of its consequences”.5   
Alfonso Troisi et al also in their article pointed out that “Cannabis abuse 
or dependence is often associated with significant premorbid psychopathology 
ranging from personality & affective disorders to psychotic disorders. In 
addition, acute adverse reactions, chronic anxiety states, depressive symptoms 
& changes in life style have been linked to chronic cannabis use by a number 
of observers. Even though, several studies have investigated the relationship 
between psychopathology & cannabis use, there are few data on the psychiatric 
comorbidity of different patterns of cannabis use. There is a continuum of 
cannabis use from occasional or experimental use of the drug to compulsive 
use patterns. As the level of involvement with the drug progresses, the risk of 
associated psychiatric disorder is likely to increase”.6 
Besides psychiatric comorbidity it has huge effect on education. 
“Cannabis use is typically initiated during adolescence, an important time of 
transition between childhood and adulthood. High school education is an 
important determinant of how well this transition is negotiated, its outcomes 
affect an individual’s educational & career opportunities and ultimately an 
individual’s life chances throughout adulthood. Given the widespread use of 
cannabis by adolescents and the fact that its intoxicating effects include 
cognitive & psychomotor impairment, there have been increasing concerns 
about its potentially adverse effects on educational performance.” 7 
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Hence, use of cannabis is associated with psychiatric comorbidity 
significantly. A lot of research papers had been published about various 
psychopathologies associated with cannabis. Researches somewhat tried setting 
the old controversies but raising new ones. This topic is relevant in the context 
that comorbid psychopathologies are very common among cannabis users in 
treatment setting in India as well as abroad. In India, data about distribution of 
psychiatric comorbidity among cannabis user are very limited. Always an 
update is needed in this area to take a stock of the prevailing situation. Hence in 
our study, we tried to evaluate various socio demographic profiles & comorbid 
psychiatric disorders in a sample of cannabis dependent treatment seeking 
patients attended our institute of Mental Health, Kilpauk. 
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REVIEW OF LITERATURE 
CANNABIS: 
Cannabis sativa is the plant from which cannabis preparations are 
obtained. Cannabis has been used by mankind since 4500 years. Cannabis 
sativa was a native of central & western Asia. Since ancient times it has been 
cultivated in Asia & Europe. In post – Columbian times, it spread to the world. 
The medicinal value of cannabis has been discovered in India and it has 
been used in Ayurveda medicine as early as 900 BC. 
BOTANICAL DESCRIPTION: 
CLASSIFICATION 
It belongs to the “Kingdom, Plantae; Subkingdom,     Tracheobionta; 
Superdivision, Spermatophyta; Division, Magnoliophyta; Class,                     
Magnoliopsida; Subclass, Hamamelididae; Order, Urticales; Family,                 
Cannabaceae; Genus, Cannabis; Species, sativa. Its binomial name is Cannabis 
sativa.”8 
“It is important to distinguish between the two familiar subspecies of the 
cannabis plant. Cannabis sativa known as Marijuana, has psychoactive 
properties. The other plant is cannabis sativa L (The “L” was included in the 
name in honor of the botanist Carl Linnaeus). This subspecies is known as 
hemp; it is a non-psychoactive form of cannabis & is used in manufacturing 
products such as oil, cloth & fuel. A second psychoactive species of the plant, 
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cannabis indica, was identified by the French naturalist Jean – Baptiste 
Lamarck, and a third uncommon one, cannabis ruderalis, was named in 1924 
by Russian botanist D.E.Janishchevisky.”9 
GROWTH HABIT 
Cultivation of cannabis plant in India is controlled. It is permitted only 
in the districts of Garhwal, Nainital and Almara in Uttarakhand state, small 
extent in Travancore & Kashmir. It takes 12 hours to 8 days for the seeds 
germinate. Seedling phase is the period of greatest vulnerability requiring 
medium to highest intensity of light, humidity in moderate levels and adequate 
soil moisture. It starts to reveal the sex by itself and the root system expands 
along with it downwards. During pre-flowering phase, development of the 
plant increase significantly with more nodes & branches. It varies about 6 – 22 
weeks for flowering phase & needs diminished light.8 
As mentioned, the cannabis plant occurs in 2 forms viz female and male 
forms. The highest concentrations of psychoactive compounds found in the 
female plant. Sinsemilla method  is the one by which female plants only are 
grown to maximize their productions of psychoactive compound . 
CHEMICAL CONSTITUENTS OF CANNABIS: 
The chemical constituents represent most of the classes of chemicals Eg. 
Nitrogenous compounds, sugars, steroids, terpenes, flavonoids, hydrocarbons, 
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amino acids etc. In these, the most important & specific class is C21 
terpenophenolic cannabinoids. 
Total number of natural 
compounds identified 
Year Reference 
423 1980 Turner et al10 
483 1995 Ross & ElSohly et al11 
489 2005 ElSohly & Slade et al12 
 
“Out of these 489 compounds, 70 were cannabinoids. Those 70 
cannabinoids were classified further to 11 categories. They are Cannabigerol 
type-7, Cannabidiols-7, Cannabichromene-5, Δ8-trans-Tetrahydrocannabinol, 
Δ9-trans-Tetrahydrocannabinol, Cannabicyclol-3, etc. other than cannabinoids, 
other compounds (419) were also classified to various chemical classes such as 
nitrogenous compounds, amino acids, proteins, enzymes, glycoproteins, sugars, 
hydrocarbons, simple alcohols, simple aldehydes, simple ketones, simple acids, 
fatty acids, simple esters, lactones, steroids etc. The details of all the chemical 
constituents of cannabis sativa are beyond the scope”.8 
PREPARATIONS OF CANNABIS:  
The common preparations of cannabis are marijuana, hash oil and 
hashish. Marijuana has been prepared from the flowering tops and the leaves of 
the cannabis plant which are dried. The potency of marijuana depends upon 
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various factors like its growing conditions, genetic characteristics, plant part 
used and the THC to other cannabinoids ratio. The highest concentrations of 
THC have been found in the flowering tops than in the stems, seeds and leaves. 
Likewise, the THC concentration varies depending upon the preparation 
as follows: 
 
 
 
 
USAGE OF CANNABIS: 
Traditionally cannabis has been smoked as joints, hand-rolled cigarettes 
which use tobacco for burning. Second most popular way is by using a water 
pipe or bong. It gives the maximum effect by delivering larger dose of 
tetrahydrocannabinol. 
Also, cannabis can be used using vaporizer, hashish also smoked mixing 
with tobacco as joint or using a pipe. As the hash oil is highly potent its few 
drops applied to a joint or cigarette or it may be heated so that its vapors 
inhaled. Bhang is a form of tea brewed from cannabis leaves and stem. 
The typical joint made of 0.5 and 1.0g of marijuana contains about  
5-150mg of tetrahydrocannabinol 20 to 70% of it reaches lung which is found 
Marijuana 0.5-5% THC 
Sinsemilla variety 7-14% THC 
Hashish 2-8% THC 
Hash oil 15-20% THC 
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in the smoke. 5-24% of the only reaches blood stream. 2-3mg of 
tetrahydrocannabinol in an occasional user produces a brief feeling of high. 
Hence a joint can provide for 2-3 individuals enough the heavy cannabis user 
might use 75 joints in a day, some may up to 420mg a day of THC.13 
PSYCHOTROPTIC EFFECTS OF CANNABIS: 
The pharmakon, the classical Greek terms describes that a substance can 
be a remedy as well as a poison. This holds good for cannabis. The effects of 
cannabis on human brain were extensively studied since last century. 
THE ENDOCANNABINOID SYSTEM: 
“The major and important psychoactive ingredient present in cannabis 
was THC-Δ9-tetrahydrocannabinol. The chemical structure of THC was first 
given by Raphael Mechoulam in1960s.  The psychological effects of THC 
occur by its stimulating action on CB1- cannabinoid 1 receptors. CB1 was first 
identified by 1988 . These receptors are G‑ protein-coupled receptor present in 
the brain. It was expressed high in the hippocampus, basal ganglia, cerebellum 
and neocortex. That are consistent with the predominant psychological and 
motor effects produced when administer THC. CB1 receptors present in 
peripheral nerves, dorsal root ganglion, dorsal horn of spinal cord and  peri-
aqueductal grey responsible for its analgesic property. CB2, the second 
cannabinoid receptor, thought previously as they were present on immune cells, 
is also found in CNS neurons, may be at low level than CB1 receptors. 
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The discovery of cannabinoid receptors led to the search for the 
endogenous agonists. The first endocannabinoid discovered is 
arachidonoylethanolamide, also termed as anandamide,( Sanskrit word ananda, 
signify ‘bliss’). The next endocannabinoids was 2‑ arachidonoylglycerol in 
1995, and followed by others. Contrast to conventional neurotransmitters, they 
are not stored as vesicles, they are synthesized only ‘on demand’ from the 
membrane phospholipids. They act via retrograde signal transmission at 
synapses. Endocannabinoids are synthesized mostly in dendrites and act 
presynaptically. It mainly inhibit release of amino-acid neurotransmitters which 
are fast acting. Ultrastructural analyses also helped us to locate key enzymes 
for the synthesis of endocannabinoid on dendritic spines. It also detected the 
location of CB1 receptors on neighbouring neurons of both GABA as well as 
glutamatergic neurons. In the hippocampus, neocortex and the striatum, CB1-
receptor expressed higher concentration on GABA-releasing neurons than on 
glutamatergic neuron terminals. Endocannabinoids are also synthesized by the 
principal output neurons, like Purkinje cells of the cerebellum, the pyramidal 
neurons of the hippocampus and cortex, spiny neurons of the striatum, and also 
by dopaminergic neurons of the midbrain. Thus by releasing endocannabinoids 
these neurons regulate their activities. 
Through this way, endocannabinoids add an another layer of neuronal 
plasticity at glutamate synapses.”14 
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MEDICINAL USE OF CANNABIS: 
Cannabis is used to treat the following aliments for thousands of years 
by Indian native practitioners. 
That includes refreshing the mind & intellect,  for treating headaches & 
migraines, generalized & localized pain, Cleaning phlegm, Curing insomnia, 
Gastrointestinal disorders, easing childbirth, aiding & quickening digestion, 
Cough, relieving dysentery, sharpening the appetite, for improving anemia & 
weight loss. And the list is very long.8 
In the Ananda kanda, there is a chapter significantly dedicated to 
cannabis solely. The perils of misuse were documented first in that text 
interestingly. 
Pharmacological studies of cannabis are also done by using various 
animal models as well as on human. 
The list of pharmacological effects is given below.  
Cannabis has various pharmacological effects discovered by many 
previous studies. It includes allergenic effect, analgesic effect, anticancer 
activity, antidepressant-like actions, antidiuretic, antiemetic, anti-inflammatory 
activity, anti-tumor activity, appetite enhancing effect, bronchoconstrictor 
activity. It also produces cell death with shrinkage of neurons, central nervous 
system depressant activity, gynecomastic effect, hemagglutinin activity, 
histamine release stimulation, hyperglycemic activity, immunomodulatory 
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effect, inflammatory effect, mitogenic effect, pancreatic effect, pancreatic 
toxicity, psoriatic effect, reproductive effect, sexual headache, spermicidal 
effect, suicidal effect and tumor-promoting effect.8 
ACUTE EFFECTS OF CANNABIS: 
People who use cannabis experience a feeling of high which are 
characterized by relaxation, mild euphoria, perceptual alterations like distortion 
of time, intensification of usual experiences like eating, watching movies, 
listening music and sex engagement. When cannabis used in a setting of social 
gathering, it is accompanied by increased sociability, talkativeness and 
infectious laughter. 
Some cognitive changes are impairment in short term memory, 
difficulty in attention and also difficulty in sustaining goal oriented mental 
activity. Also there might be impartment of motor coordination and skilled 
motor activity. 
CANNABIS DEPENDENCE:  
Nearly 90% of people who use cannabis and those who were older than 
15 years reported that they had no problems with their use of cannabis. But, 
harms due to cannabis use are established well; particularly regular users of 
cannabis are at high risk to those harms. 
In a survey conducted in 2004 in Canada, showed approx. 9% of people 
who use cannabis may go to the level of addiction compared with alcohol, 
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cocaine and heroin, it was 11%, 15%, and 24% respectively. Though they do 
not qualify for addiction by criteria, they still have problems related with 
cannabis use like problems in health, social or legal issues.15 
The risk of dependence increases with increased frequency of use, daily 
use, earlier the age of initial use and longer duration. 
High risk of dependence associated with certain factors like deviant 
behavior in children and adolescence, poor academic achievement, 
maladjustment and personal distance, poor relationship with parents, family 
history of drug use and earlier use.13 
CANNABIS WITHDRAWAL:  
Cannabis withdrawal syndrome a phenomenon that is common and 
clinically significant among adult cannabis users who stop using cannabis 
without seeking treatment. 
DSM 5 proposed certain criteria to diagnose CWS. Those are 3 or more 
out of 7 symptoms occur within several days after cessation of heavy and 
prolonged use of cannabis.16 
a) Irritability, aggression or anger 
b) Anxiety or nervousness  
c) Insomnia 
d) Weight loss or decreased appetite 
e)  Restlessness 
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f) Depressed mood 
g) At least one of following physical symptoms – stomach ache, 
tremors / shakiness, fever, headache, sweating, chills.17 
 Commonly these symptoms occur within 24 hours of quitting the use of 
cannabis, peaks in the first week and lasts for 1-2 weeks approximately.18 
 Various studies commonly reports that the most common withdrawal 
symptoms were behavioral and affective in nature, although a group of 
adolescents experienced physical symptoms also.18 
RISK FACTORS FOR CANNABIS USE: 
Various authors classified risk factors for cannabis use in many ways. 
Kandel et al19 classified that the following were the risk factors identified for 
the use of cannabis. 
• Biomedical which includes genetic 
• Psychological 
• Psychiatric 
• Social 
• Financial 
• Environmental 
In general the risk factors highly associated with the use of cannabis 
were explained under the following headings: 
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Socio-environmental factors: 
The following are the high risk factors associated with use of cannabis -
Male gender, low socioeconomic status, adverse life events, younger age, and 
living in urban place. 
Substance related factors: 
It includes use of tobacco, use of alcohol, AUD, attitudes towards the 
use of drug, opportunities to use drugs, use of nicotine or cannabis by peers. 
Intrapersonal factors: 
Personality attributes: low self-esteem, novelty seeking, and loneliness. 
Psychopathology: mood/ mental/ anxiety disorders. 
 Childhood factors: insecurity, social incompetence, behavioral 
problems. 
Interpersonal factors: 
 Current family situation: low parental attachment, low family caring, 
smoking in father, leaving home within age 18. 
 Childhood family situation: poor parental relationship with the child, 
conflicts within family, sexual abuse, history of alcohol use and problems 
between parents, not brought up by any of the parent.20  
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SOCIO DEMOGRAPHIC VARIABLES: 
Carolyn coffey et al did a study and they found the peak use of cannabis 
at 20 years. Males reported use of cannabis more frequently than females 
consistently. They also found smoking cigarettes; high risks drinking of 
alcohol, cannabis use in peers, antisocial behavior were associated with 
adolescent use during mid-school period (14.9-15.9 years).21 
12% of adults and 27% of adolescents who use cannabis were identified 
as dependent by them. Adolescents who use cannabis regularly are at higher 
risk of use of other illicit substances, tobacco and alcohol. 
Carolyn coffey et al concluded that the following harms were 
unequivocally proved among heavy users of cannabis in adolescence. 
That include 
1. High risk for dependence 
2. Other substance abuse  
3. School dropout and academic failure 
4. Persisting problems in mental health.21 
Dennis et al in their article noted that 3 wave’s patterns among new 
users of cannabis which were overlapping and more in younger age cohorts of 
use. First wave, during 1960’s and early 1970’s where the new user cohort 
comprised of persons who aged 18 years and older. Second ware in mid to late 
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1970’s, comprises of persons between ages 15 and 17, and also who started at 
less than 15yrs of age begin to increase.22 
In the third wave, 1990’s more people around 40% begin to use cannabis 
at less than 15yrs and it grows rapidly. By 1998, early use of substance 
becomes the most common. 
S.NO Substance % under 
18years 
% Under 
15years 
1 Tobacco 79% 45% 
2 Alcohol  67% 29% 
3 Cannabis  63% 24% 
4 Inhalants  64% 28% 
5 Hallucinogens  51% 11% 
 
   Use of cannabis regularly and dependence were associated with broad 
variety of mental disorders which includes CD, ADHD, depression, anxiety. 
Particularly use of cannabis in vulnerable persons precipitate schizophrenia and 
in people with schizophrenia worsen prognosis.22 
And also health related problems associated Dennis et at with the use of 
cannabis are interference in normal development of adolescents aggravation of 
bronchial asthma, greater risk of bronchial and lung cancer, road traffic 
accidents and high risk of STD.  
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PSYCHOSOCIAL FACTORS ASSOCIATED WITH CANNABIS 
ABUSE: 
“The term psychosocial factors refer to the psychological and social 
factors that influence mental health. Social influences such as peer pressure, 
parental support, cultural and religious background, socioeconomic status and 
interpersonal relationships all help to shape personality and influence 
psychological make-up”.23 
Though all psychiatric disorders has influenced by a range of 
psychosocial factors, substance use disorder share a lot. As mentioned earlier 
cannabis has a broad range of psychological and physical disorders, so there is 
a great need to explore the various factors which lead to and contribute to the 
development and continuance of CUD. 
Various factors across multiple domains contribute to the development 
of CUDs. Particularly, variables in the following domains contribute to use of 
cannabis and dependence. They are peer, family, personality attributes, 
neighborhood, work and other substance use.24 
 Brook et al in 2011 did a study on psychosocial factors related to CUDs. 
The semi structured variables used in that study was adopted by us in our 
study. Regards to personality attributes, several studies identified certain traits 
in personality were associated with a “syndrome of under control” which 
includes impulsive behavior, disinhibition and aggressive behavior. They also 
found that depressive and anxiety disorders were associated with high risk of 
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CUDs. In regarding family factors, levels of mental attachment, partner 
relationship plays an important role. Similarly association with drug using 
peers is significantly associated with use of cannabis and dependence. Work 
related measures like frequent asterism and poor occupational achievement 
were related to use of cannabis. Neighborhood characteristics such as violence 
and drug availability were importantly associated with CUDs.24 
 Brook et al conclude that male adults were 4 times more likely to 
diagnose as CUDs than females. And also they stated that “CUDs were 
predicted by the cumulative number of psychosocial and demographic risks. 
They postulate in accord with FIT (Family Interactional Theory ), increase in 
the total number of psychosocial risks with which an individual must cope is 
associated with a corresponding increase in substance use in adolescents and 
young adults”.24 
PSYCHIATRIC MORBIDITY ASSOCIATED WITH CANNABIS: 
According to DSM 5, the prevalence of CUD is around 3.4% in 12-17 
years of age & 1.5% in adults aged 18 years & older. And also rates of CUD 
are higher among males (2.2%) than females (0.8%). 
The onset of CUD is during adolescence or during young adulthood. 
The progression of CUD is more rapid in adolescents especially those with 
conduct problems. And also, cannabis use prior to age 15years is a strong 
predictor of the CUD, other substance use disorder & mental illness in young 
adulthood. 
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DSM 5 elaborates various risk factors for CUD viz temperamental, 
environmental, genetic & physiological. The use of cannabis has related to a 
decrease in prosocial and goal- directed activities which was labeled as 
amotivational syndrome. It manifests as poor performance in school & 
problems in employment. Chronic use of cannabis contribute to the onset or 
exacerbation of many mental illness, particularly raised concern about it as an 
important causal factor in the onset of schizophrenia and other psychosis.16 
 Use of cannabis is associated with poor satisfaction in life, more mental 
health hospitalization & treatment. It has higher incidence of depressive 
disorder, anxiety, attempting suicide & conduct problems. Persons with 
lifetime or past year CUD have more than 50% & 53% of alcohol & tobacco 
use disorder respectively. Among persons who seek treatment for CUD has 
74% problematic use of other substance. Also, among them, MDD accounts for 
11%, anxiety disorder 24% & bipolar I disorder 13%. Among personality 
disorders, 30% has antisocial, 19% obsessive compulsive & 18% paranoid 
personality.16 
CANNABIS AND PSYCHOSIS: 
 Both cross sectional studies and longitudinal studies gives evidence for 
the strong association of use of cannabis and persistent psychosis. The studies 
include “The Swedish military conscript cohort, NEMESIS – the Netherlands 
Mental Health survey and incidence study, the German prospective early 
developmental stages of psychopathology study (EDSP), the Dunedin cohort 
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and the Christ church Health and Development study birth cohort (CHDS)”25. 
All these studies have their own pros and cons. 
 The association strength between cannabis exposure and the onset of 
psychosis in the general population is modest. The relative risk of 
schizophrenia after exposure to cannabis was found to be 1.4 in a systematic 
review of about 35 longitudinal studies. This relative risk is achieved after 
adjusting about sixty confounding factors like socioeconomic variables, 
personality traits, other substance use and other problems in mental health. 
There is indirect but strong evidence that was seen in cannabis induced 
psychosis is converted to schizophrenia.25 
In laboratory as well as epidemiological studies they found that a range 
of psychosis effects induced by cannabinoids. The causal role of cannabis in 
the onset of psychotic disorder is magnified by various factors like exposure to 
cannabis at earlier age, greater quantities, long time course, these with genetic 
vulnerability or with history of abuse in childhood. 
The association between the use of cannabis and psychotic illness can be 
explained as  
1. Psychosis or schizotypy traits due to direct pharmacological actions 
of cannabis. 
2. Use of cannabis due to psychosis or schizotypy as a coping means. 
3. Another factor associated with both i.e. psychosis and cannabis.26 
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D’souza et al in 2005 established that case of cannabis increase the 
positive symptoms of psychosis.27  Ameri in 1999 itself found that 
cannabinoids increase dopaminergic neurons activity in VTA (Ventral 
Tegmental Area) in Mesolimbic dopamine pathway.28 
 NESARC study postulate that both psychosis and schizotypal 
personality disorder prevalence increases as the use of cannabis increases in a 
dose – dependent relation. Those who use cannabis when compared with non-
user had a prevalence of symptoms of SPD in a significantly increased level in 
all domains viz positive, negative, cognitive, perceptual, disorganized and 
interpersonal.29 
 In summary, exposure to cannabinoids can produce a range of transient 
features, cognitive deficits and abnormalities in psychopathology that bear a 
resemblance to some features of schizophrenia. Also in individuals with 
psychotic disorder, it exacerbates psychotic symptoms, has negative effect on 
the illness course and trigger relapse. At last, in adolescence exposure to 
cannabinoids has a high risk of psychosis in late life. However, it also should 
be kept in mind that majority of persons who use cannabis do not experience 
psychosis of any kind.25 
 Cyril D’ souza et al in 2009 stated that cannabinoids could induce 
transient positive, negative, cognitive symptoms of schizophrenia and 
exacerbate those symptoms in already schizophrenic patients. Schizophrenics 
and people who are prone for psychosis are more likely to experience those 
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symptoms after exposure to cannabis than healthy individuals. The 
cannabinoids increase dopaminergic activity, reduce GABA and glutamatergic 
transmission that contribute to the production of these symptoms of 
schizophrenia but exact mechanism is still unclear. They finally conclude in 
their article that exposure to cannabis can be a component or a cause 
contributing that interacts with genetic, environmental and other unknown 
factors to culminate in schizophrenia.30 
Myles et al in a systematic review conducted in 2012 examined nearly 
80 papers and compared to tobacco smoking, cannabis smoking and the onset 
of psychosis. They found that use of cannabis was associated with early mean 
age of onset (almost 3 years earlier) of psychosis, both schizophrenia spectrum 
disorders and affective subtypes also whereas use of tobacco at that age had no 
effect on onset of psychosis. Hence this meta-analysis also added evidence for 
the causal association of use of cannabis and early onset of wide range of 
psychotic disorders.31 
CANNABIS AND AFFECTIVE DISORDERS: 
 Gibbs et al in 2014 conducted a systematic review on cannabis use and 
manic symptoms. They found only 6 articles regarding their inclusion criteria. 
They stated that psychosis and mania share the same etiological mechanisms. 
Example, dopaminergic system sensitization raises the risk of schizophrenia as 
well as mania. They conclude that use of cannabis was almost 3 fold increase 
in association in the odds of symptoms of mania indicate a moderate 
association. They also suggested that this area of research is like neglected 
clinical issue.32 
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 Lev Ran et al in 2013 did a meta-analysis and systematic review of 57 
longitudinal studies upon the association of cannabis use and depression. They 
found that use of cannabis has been associated with moderate risk increase in 
developing depression.33 
 Hercilio et al conducted a study on treatment seeking cannabis 
dependent persons about their psychiatric comorbidity in 2014. They found that 
major depression accounts for 22% of psychiatric disorders among cannabis 
dependent individuals. Next come, anxiety disorders 20% schizophrenia 9%.34 
 Degenhardt et al conducted a systematic review to explore the 
association between the use of cannabis and depression. He stated that Delta 9 
the affect brain serotonin and other neurotransmitters to produce symptoms of 
depression. And also heavy users can precipitate indirectly depression 
symptoms by causing impairment in psychosocial adjustment like school drop-
out, reduced capacity to earn. Furthermore thy stated that individuals who were 
depressed begin to use cannabis to curb their depressive symptoms. Thirdly 
they explained about some factors common to both use of cannabis and 
depression which are personality, biological, social, environmental or 
combination of some of these.35 
 One prospective study by Bovasso in Baltimore site reported that use of 
cannabis at baseline on follow up 4.5 times more chance to report symptoms of 
depression and 4.6 fold increases to report suicide ideation compared with 
nonusers.36 
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 Horwood et al presented an integrative analysis on data from 4 cohort 
studies from Australia in 2012 about the association of use of cannabis 
frequency and the symptoms of depression severity. They conclude that use of 
cannabis more frequently has been associated with moderate increase in 
depressive symptoms. Also found that the associations is stronger among 
adolescents and thereafter decreases. 37 
CANNABIS AND COGNITION: 
 Acute intake of cannabis produces impairment in cognitive functioning 
especially executive functions like attention and working memory and 
hippocampus dependent memory and learning. The underlying mechanism was 
described as endocannabinoids were the key component in the mechanism of 
neuroplasticity. Chronic use of cannabis show cognitive impairment. But the 
persistence of this impairment after abstinence is still controversy. But various 
studies proved that the use of cannabis before 16 years associated with 
persistent deficits in performing tasks that need focused attention and also 
associated with low IQ scores on verbal component.14 
 Cohen et al in 2008 suggested that cannabinoids exposure result in 
change in functions of CB1 found brain regions, change in cerebral perfusion 
and change in neuro modulatory systems relevant to cognition like GABA, 
Dopamine and Glutamate.38 
 A meta-analysis done by Rabin et al in 2011 conclude that use of 
cannabis has been associated with modest but possibly clinically insignificant 
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effects on neurocognition especially in schizophrenia. They conclude that 
future research further needed in this area.39 
 Pope et al in their study conclude that use of cannabis at early age before 
17 years differed significantly from late onset users and controls on variety of 
measures most importantly verbal IQ.40 
 Many studies showed that memory functions baseline impairment in 
continue at 7 days of abstinence but apparently recovered fully after abstinence 
of 28 days. Adolescents who use cannabis were shown to have impairment in 
memory, psychomotor speed, attention and ability to plan even after 23 days 
and more of abstinence. And also they found alterations in blood flow  
to temporal lobe and cerebellum even after 28 days of abstinence from 
cannabis. 41 
CANNABIS AND EDUCATION: 
 The concern is growing about cannabis use among adolescents and its 
impact on education. Use of cannabis has been associated in adolescents with 
lower grade average, decreased satisfaction in school, more negative attitudes 
upon school and overall poor school performance. Hence the evidence 
suggested that cannabis use early place adolescents at high risk of decreased 
educational attainment, particularly leaving school early.42 
A research report by Lynskey et al in 2002 reported that use of cannabis 
by persons aged less than 15 years and regular users were associated with high 
rates of early school dropouts, even after confounding variables such as 
familial background, mental illness and use of other substances excluded. The 
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most acceptable reason behind this finding is early use of cannabis definitely 
associated with acceptance of anti-conventional style of life, of which school 
dropout is an indicator.42 
Meier et al in 2012 did a prospective study by following 1037 birth 
cohorts for 20 years. They concluded that average of approximately 6 points 
decline in IQ who uses cannabis persistently. Likewise the study concludes that 
certain domains of neuropsychological functions specifically involved. It 
includes working memory, perceptual reasoning index, processing speed index 
and verbal comprehension index. But the difference is not that much significant 
statistically. This study added evidence that impairment interfere with day to 
day functioning of the persistent user of cannabis and also onset of cannabis 
use during adolescent showed persistent impairment even after 1year or more 
abstinence from cannabis. It suggests that cannabis may have some neurotoxic 
effects on developing brain during adolescence.43 
With all these reviews on the back of mind, we tried to find socio 
demographic profile, various psychosocial factors and distribution of 
psychiatric comorbidity among persons who abuse cannabis. Since our reviews 
found that persons who start to use cannabis during adolescence have some 
unique psycho social factors and also the psychiatric comorbidity too. Hence in 
our post hoc analysis, we tried to compare socio demographics & psycho social 
factors between adolescent onset & adult onset cannabis abusers. 
 
 
 
 
28 
AIMS & OBJECTIVES 
AIM 
To evaluate psychosocial factors and psychiatric comorbidity among 
persons abusing cannabis. 
OBJECTIVES 
1. To evaluate sociodemographic profile among persons abusing cannabis. 
2. To evaluate problematic domains among persons abusing cannabis. 
3. To evaluate withdrawal symptoms among persons who abstain from 
cannabis. 
4. To estimate the distribution of psychiatric comorbidity among persons 
abusing cannabis. 
5. To estimate sociodemographic variables and psychosocial attributes 
between adolescent and adult onset of cannabis use. 
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HYPOTHESIS 
NULL HYPOTHESIS 
There is no significant sociodemographic profile among persons abusing 
cannabis. 
There is no significant psychiatric comorbidity among persons abusing 
cannabis. 
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METHODOLOGY 
SETTING: 
This study was conducted at the Institute of Mental Health, Madras 
Medical College, a tertiary care center of Tamilnadu. The necessary approval 
for conduct of the study was obtained from Institutional Ethics Committee, 
Madras Medical College, Chennai. 
STUDY POPULATION: 
Subjects who use cannabis attending our outpatient department and also 
got admitted in Institute of Mental Health were included in this study. 
SAMPLE SIZE: 
A total of 100 subjects who use cannabis were included in this study. 
SAMPLE SIZE CALCULATION: 
 The sample size calculated according to the formula 
Ƣ2*p*(1-p)/ d2  
According to previous studies the prevalence of psychiatric comorbidity 
among persons abusing cannabis was 60%44 to 80%45. So we took average of 
70% prevalence. Precision was assigned as 10%. 
1.96*1.96*70*30/102 = 80.67 
 
 
 
31 
PERIOD OF STUDY: 
This study was conducted for a period of 4 months from March 2017 to 
June 2017. 
SAMPLING METHOD: 
Convenience sampling  
STUDY DESIGN: 
Descriptive study. 
INCLUSION CRITERIA: 
1. Adult patients attending Institute of Mental Health with history of 
current cannabis use. 
2. Those who fulfill criteria for cannabis dependence as per ICD10. 
EXCLUSION CRITERIA: 
1. Previous history of psychiatric illness before abusing cannabis. 
2. Acute intoxication of any illicit substance. 
3. Head injury / neurological illness / hearing impairment. 
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OPERATIONAL DESIGN: 
After obtaining the written consent from the participants as required by 
the international ethics committee the following questionnaire were given to all 
subjects 
1. Semi structured proforma 
2. Marijuana problem scale 
3. The Cannabis withdrawal scale 
4. MINI PLUS structured clinical interview.  
DESCRIPTION OF THE INSTRUMENTS: 
1. SEMI STRUCTURED PROFORMA 
This was used to collect the subject’s sociodemographic profile viz age, 
gender, educational attainment, occupation, marital status, place of residence, 
socioeconomic status, religion. 
The second part was used to assess psychosocial factors under the following 
headings 
1. Personal attributes 
2. Marital relationship 
3. Peer relationship 
4. Neighborhood 
5. Work 
6. Other substance use 
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Under personal attributes, violence towards others & impulsivity were 
considered. 
Relationship with partner & peer were considered 
Drug availability in neighborhood, work achievement was enquired. 
Comorbid substance use & family history of substance use disorder & 
mental illness were collected. 
2. MARIJUANA PROBLEM SCALE 
Stephens et al developed this “Marijuana problem scale”. It was a self- 
report that helps to identify the areas in life affected by cannabis use. It consists 
of 19 items under the following sub headings 
1. Self esteem 
2. Social relationship 
3. Work & finances 
4. Motivation & productivity 
5. Physical health 
6. Memory impairment 
7. Legal problems 
Those items were rated as serious problem (2), minor problem (1) or no 
problem (0). The items endorsed as minor or serious problem has been counted 
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to get a total number of marijuana related problem. This measure was proved to 
be internal consistency among persons abusing cannabis cronbach’s  
alpha =0.89.46 
3. CANNABIS WITHDRAWAL SCALE 
CWS has 19 items. It should be from 0 to 10, as per how he / she felt 
over the past 24 hours. 0- not at all, 10- extremely. Total score is achieved by 
summing up all the values. Max score – 190. This 19 items scale has high 
internal reliability score. The Cronbach’s alpha of 0.91 which supports this 
scale is a reliable measure to assess withdrawal of cannabis.47 
3. MINI PLUS   
First development by Dr. Sheehan & Dr. Lecrubrier of france. It is short 
& structured interview for diagnosis, developed jointly by clinicians & 
psychiatrists in the U.S & Europe, for ICD 10 & DSM IV disorders. It was 
designed to help the multicenter trials and epidemiology studies as short & 
accuracy in psychiatric diagnosis. It has very short administration time of 15 
minutes. It has good test-retest reliability & inter -rater reliability. 
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OPERATIONAL DESIGN 
 
Subjects abusing cannabis attending institute of Mental Health 
    ICD 10 substance dependence criteria 
                     100 subjects with cannabis dependence syndrome taken 
 
• Objective 1 
Semi structured proforma to compare 
sociodemographic profile 
• Objective 2 
Marijuana problem scale 
• Objective 3 
Cannabis withdrawal scale 
• Objective 4 
Mini plus (to evaluate psychiatric comorbidity) 
 
 
 
Those who started abusing cannabis                            Started abusing cannabis 
> 19years 
In adolescent period age group 
< 19 years 
 
 
Objective 5 
 
 
36 
Comparing both groups for the following 
 Duration of cannabis use 
 Duration of illness 
 Family history of mental illness / substance use 
 Psychosocial attributes  
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STATISTICAL ANALYSIS 
 
The study design is cross sectional and prevalence study. Most of the 
variables used in our study are categorical in nature. Hence frequency and 
prevalence was calculated. 
Pearson’s chi square test also known as Chi square test for independence 
and Chi square test of association was used to find if there was any relationship 
between two categorical variables. Eg: Is there any significant distribution of 
marital status among the two groups of persons abusing cannabis. 
ANOVA was used to compare between the two means. Eg. Mean 
withdrawal score in different groups. 
Bonferroni test was used in our study. This allows to do multiple 
comparison in an ANOVA situation. This method is valid for both equal and 
unequal sample sizes. 
P value of 0.05 is taken as significant. 
  
 
 
38 
RESULTS AND OBSERVATIONS 
SOCIODEMOGRAPHIC PROFILE: 
The prevalence percentage of various sociodemographic variables 
among treatment seeking cannabis dependent persons are given below: 
TABLE 1 
DISTRIBUTION OF GENDER: 
Gender Frequency Percentage 
Male 100 100% 
Female 0 0% 
 
 
In our study, those who seek cannabis related problems were 
predominantly male i.e 100% no females registered for cannabis related 
problems during our study period. 
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TABLE 2 
AGE AT PRESENTATION OF CANNABIS USE DISORDERS 
Age group Frequency Percentage 
<15years 0 0% 
15 – 20years 26 26% 
21 – 25years 35 35% 
>25years 39 39% 
 
 
 
39% of individuals present with CUDs were above 25 years of age.  
Mean age at the time of presentation: 25.54 years 
95% confidence interval - 24.16 – 26.92 years. 
Standard deviation: 6.95years 
Range: 17 – 49 years 
Median: 24years  
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TABLE 3 
DISTRIBUTION OF PLACE OF RESIDENCE 
Place Prevalence Percentage 
Urban 70 70% 
Semi-urban 9 9% 
Rural 21 21% 
 
 
70% belongs to urban area 
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TABLE 4: 
DISTRIBUTION OF MARITAL STATUS 
Marital Status Frequency Percentage 
Single 77 77% 
Married 20 20% 
Divorced 3 3% 
 
 
 
77% individuals with CUDs were unmarried. 
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TABLE 5 
DISTRIBUTION OF EDUCATION STATUS AMONG THE GROUP 
Education Prevalence Percentage 
Uneducated 2 2 
1 – 5 15 15 
6 – 10 62 62 
Higher secondary / ITI 10 10 
Degree / Diploma 11 11 
 
 
79% of people were below 10th standard 
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TABLE 6 
DISTRIBUTION OF SOCIOECONOMIC STATUS 
SE Status Frequency Percentage 
Lower 96 96% 
Middle 4 4% 
Higher 0 0% 
 
 
96% belongs to low socioeconomic status. 
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TABLE 7 
OCCUPATIONAL STATUS AMONG THE GROUP 
 Frequency Percentage 
Unemployed 36 36% 
Unskilled 27 27% 
Semiskilled 13 13% 
Skilled 24 24% 
 
 
 
36% were unemployed among persons who presented with CUDs. 
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TABLE 8 
DISTRIBUTION OF RELIGION 
Religion Frequency Percentage 
Hinduism 88 88% 
Islam 4 4% 
Christianity 8 8% 
 
 
88% belongs to Hinduism. 
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TABLE 9 
FAMILY HISTORY 
Family history Prevalence Percentage 
Family H/o of mental illness 13 13% 
Family H/o of substance use disorder 68 68% 
 
 
87% people has family H/o SUD whereas only 13% has mental illness 
in family. 
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TABLE 10 
AGE AT ONSET OF CANNABIS ABUSE 
 Frequency Percentage 
≤ 19 years  68 68% 
20 years and above 32 32% 
 
 
68% begin to abuse cannabis in their adolescent period 
Mean age of onset→ 18.36 years 
95% Confidence Interval – 24.16 – 26.92 years 
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Range → 5 – 34 years 
Standard deviation→ 5.20 years 
Median – 17years  
SCATTER DIAGRAM SHOWING THE AGE OF ONSET OF 
CANNABIS ABUSE 
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TABLE 11 
DURATION OF CANNABIS ABUSE AT THE TIME OF PRESENTATION 
Duration in years Frequency Percentage 
< 5 years 54 54% 
5 – 10 years 26 26% 
>10 years  20 20% 
 
80% of people present with cannabis related problems within 10 years dictation 
of use 
Mean duration of dependence – 7.15 years 
 95% Confidence Interval -  6.03 – 8.27 years 
Range – 1 -26 years  
Standard Deviation – 5.66 years 
PIE DIAGRAM SHOWING THE DURATION OF CANNABIS 
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TABLE 12 
PREVALENCE OF PSYCHOSOCIAL ATTRIBUTES AMONG THE 
SAMPLE OF CANNABIS DEPENDENT PERSONS 
Variable Frequency Percentage 
Violence prone  27 27% 
Impulsive  53 53% 
Deviant behavior  32 32% 
Drug using peers  45 45% 
Drug availability  33 33 
Skipping at work 43 43% 
Poor achievement  56 56% 
Comorbid substance use 
Nicotine  48 48% 
Alcohol  66 66% 
Others  27 27% 
 
More than 50% people were impulsive, had poor achievement in work / 
school and abusing alcohol. 
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CHART 5: BAR CHART REPRESENTING THE PREVALENCE OF 
PSYCHOSOCIAL ATTRIBUTES OF THE SAMPLE 
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CHART 6: BAR CHART REPRESENTING  
COMORBID SUBSTANCE USE: 
 
 In our sample 66% consume alcohol, 48% use nicotine and 27% used 
other substances like fevibond, Nitrazepam tablets and tobacco impurities like 
HANS. 
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TABLE 13 
DISTRIBUTION OF PSYCHIATRIC COMORBIDITY  
AMONG 100 CANNABIS DEPENDENT PEOPLE 
DIAGNOSIS AS PER MINI PLUS PERCENTAGE 
Psychotic disorders 61% 
Manic episode 11% 
Depression 1% 
ASPD 6% 
Non-alcohol psychoactive substance use disorder 21% 
 
CHART 7: PIE DIAGRAM SHOWING THE DISTRIBUTION OF 
PSYCHIATRIC COMORBIDITY AMONG THE SAMPLE 
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TABLE:14 
PREVALENCE OF COMORBID ALCOHOL ABUSE AMONG 
PSYCHIATRIC COMORBIDITY 
PSYCHIATRIC 
COMORBIDITY 
NO ALCOHOL 
ABUSE 
N (%) 
WITH ALCOHOL 
ABUSE 
N (%) 
Psychotic disorders 22 (36.1%) 39 (63.9%) 
ASPD 1(16.7%) 5 (83.3%) 
Non Alcohol 
Psychoactive Substance 
use disorder 
 
8 (38.1%) 
 
13 (61.9%) 
Manic episode 3 (27.3%) 8 (72.7%) 
Depression 0 1 (100%) 
  
 Among all the psychiatric comorbidity, more than 50% have comorbid 
alcohol abuse. 
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TABLE:15 
VARIABLES RELATED TO THE PSYCHOSIS IN THE SAMPLE: 
61% had psychotic disorders in our study. 
Mean age at presentation 25.54years 
Mean age of onset of cannabis abuse 18.36years 
Mean duration of cannabis abuse 7.15years 
Mean duration of illness 24.98 months 
Percentage had family history of mental 
illness: (N=10) 
16.4% 
Percentage had family history of substance 
use disorder: (N=42) 
68.8% 
Percentage of alcohol abuse: (N=39) 63.9% 
Percentage of alcohol dependence: (N=24) 39.3% 
 
 From these variables, we understand when a person starts to use 
cannabis by average age of 18.36years for the mean duration of 7.15years 
present with psychosis by the age of 25.54years. In that only 16.4% have 
family history of mental illness whereas 68.8% have family history of 
substance use. Similarly 63.9% have comorbid alcohol use.  
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TABLE: 16 
PREVALENCE OF ALCOHOL DEPENDENCE 
PSYCHIATRIC 
COMORBIDITY 
ALCOHOL 
DEPENDENCE 
PERCENTAGE 
PSYCHOSIS 24 39.34% 
ASPD 3 50% 
MANIA 4 36.3% 
DEPRESSION 1 100% 
NON ALCOHOL 
PSYCHOACTIVE 
SUBSTANCE USE 
5 23.8% 
 
POST HOC ANALYSIS  
Comparison of sociodemographic variables, psychosocial attributes 
between adolescent and adult onset cannabis abusers. 
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Table 14 
Comparison of sociodemographic variables between adolescent and 
adulthood onset of cannabis abuse 
VARIABLES 
 
≤19 years  
N=68 
>19 years 
N=32 
ᵧ P 
Marital status 
Divorced 2(2.9%) 1(3.1%) 
16.758 <0.001 Married 6(8.8%) 14(43.8%) 
Single 60(88.2%) 17(53.1%) 
Occupation 
Unemployed  27(39.7%) 9(28.1%) 
3.773 0.287 
Semiskilled  6(8.8%) 7(21.9%) 
Skilled  17(25.0%) 7(21.9%) 
Unskilled  18(26.5%) 9(28.1%) 
Place 
Rural  11(16.2%) 10(31.2%) 
4.266 
0.118 
Semiurban  5(7.4%) 4(12.5%)  
Urban  52(76.5%) 18(56.2%)  
SE Status 
Lower  65(95.6%) 31(96.9%) 
0.094 0.759 
Middle  3(4.4%) 1(3.1%) 
Religion  
Christian  5(7.4%) 3(9.4%) 
3.754 0.153 Hindu  62(91.2%) 26(81.2%) 
Islam  1(1.5%) 3(9.4%) 
 
Statistically significant difference in marital status i.e. most of the 
adolescent onset cannabis users were unmarried. Whilst occupation, place, SE 
status, religion there was no significant difference between these 2 groups. 
 
 
 
58 
CHART 8 
BAR CHART SHOWING COMPARISON OF DEMOGRAPHIC FACTORS 
AMONG ADOLESCENT & ADULT ONSET CANNABIS ABUSE 
 
CHART 9 
BAR CHART SHOWING COMPARISON OF DEMOGRAPHIC VARIABLES 
BETWEEN ADOLESCENT & ADULT ONSET CANNABIS ABUSE
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
MARITAL 
STATUS<19YRS 
S,M,D
MARITAL 
STATUS>19YRS 
S,M,D
PLACE<19YRS 
U,S,R PLACE>19YRS 
U,S,R
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
OCCUPATION 
<19YRS 0, UN 
,SEMI, SKILLED
OCCUPATION 
>19YRS 0, UN, 
SEMI, SKILLED
SE STATUS 
<19YRS L, M SE STATUS 
>19YRS L, M
 
 
59 
 
TABLE 15 
COMPARISON OF PSYCHOSOCIAL ATTRIBUTES BETWEEN 
ADOLESCENT ADULT ONSET CANNABIS ABUSER. 
S.NO  
≤ 19 years 
N 68 
>19 years 
N 32 
ᵧ P 
1 Violent prone 21(30.9%) 6(18.8%) 1.625 0.202 
2 Impulsive 43(63.2)% 10(31.2%) 8.97 0.003 
3 Deviant peer 24(35.3%) 8(25.0%) 1.641 0.440 
4 Drug using peer 38(55.9%) 7(21.8%) 10.168 <0.001 
5 Drug availability 27(39.7%) 6(18.7%) 4.238 0.038 
6 Skipping at work 34(50%) 9(28.1%) 4.248 0.039 
7 Work achievement 38(55.8%) 18(56.2%) 4.183 0.123 
8 Nicotine use 34(50%) 14(43.75%) 0.341 0.560 
9 Alcohol use 45(66.1%) 21(65.6) 0.003 0.957 
10 Family H/o MI 8(1.7%) 5(15.6%) 0.327 0.568 
11 Family H/o SUD 47(69.1%) 21(65.6%) 0.122 0.727 
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CHART 10 
COMPARISON OF PSYCHOSOCIAL ATTRIBUTES BETWEEN 
ADOLESCENT & ADULT ONSET CANNABIS ABUSE 
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TABLE 16: 
COMPARISON OF MPS BETWEEN ADOLESCENT AND  
ADULT ONSET CANNABIS ABUSE 
 ≤ 19 years  >19 years Chi square P value 
Social 
 
1 45(66.2) 1(3.1) 
4.240 0.237 2 20(29.4) 24(75.0) 
3 3(4.4) 7(21.9) 
Academic / 
Occupation 
1 64(94.1) 31(96.9%) 
0.348 0.555 
2 4(5.9) 1(3.1) 
Physical 
0 1(1.5%)  
1.195 0.550 1 62(91.2%) 31(96.9) 
2 5(7.4%) 1(3.1) 
Financial 
1 66(97.1) 31(96.9) 
0.003 0.960 
2 2(2.9) 1(3.1) 
 
Psychological 
1 47(69.1%) 24(75%) 
3.827 0.281 2 18(26.4%) 7(21.8%) 
3 3(4.5%) o 
 
Both groups showed no difference in experiencing problems due to use 
of cannabis. 
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CHART 11: 
BAR CHART SHOWING THE SEVERITY OF  
CANNABIS PROBLEMS AMONG THE SAMPLE 
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Chi square value 4.295 
P value 0.117 
 
There is NO significant association between duration of cannabis abuse 
and age of onset of cannabis. 
 
 
 
TABLE 17: 
COMPARISON OF AGE ONSET GROUP WITH  
DURATION OF CANNABIS USE 
AGE AT ONSET OF CANNABIS 
ABUSE 
DURATION OF CANNABIS USE 
Total 
<5 YEARS 5-10 YEARS 
> 10 
YEARS 
 
<=19 years 
Count 32 21 15 68 
% within group 47.1% 30.9% 22.1% 100.0% 
ABOVE 19  
YEARS 
Count 22 5 5 32 
% within group 68.8% 15.6% 15.6% 100.0% 
Total 
Count 54 26 20 100 
% within group 54.0% 26.0% 20.0% 100.0% 
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CHART 12 
BAR CHART SHOWING COMPARISON OF DURATION OF 
CANNABIS ABUSE BETWEEN ADOLESCENT &  
ADULT ONSET CANNABIS ABUSE 
 
People who use cannabis after the age of 19years present more with 
problems within 5years of use. 
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TABLE 18 
COMPARISON OF DURATION OF CANNABIS ABUSE AND 
CANNABIS WITHDRAWAL SYMPTOMS 
DURATION 
OF 
CANNABIS 
ABUSE 
N Mean Std. Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
<5 YEARS 54 9.4074 5.97643 .81329 7.7762 11.0387 
5-10 YEARS 26 16.9231 9.45272 1.85383 13.1050 20.7411 
ABOVE 10 
YEARS 20 22.7000 6.46529 1.44568 19.6742 25.7258 
Total 100 14.0200 8.87395 .88740 12.2592 15.7808 
 
COMPARISON OF WITHDRAWAL BY ANOVA: 
 Sum of 
Squares 
Df Mean 
Square 
F Sig. 
Between 
Groups 2874.877 2 1437.438 28.334 .000 
Within Groups 4921.083 97 50.733   
Total 7795.960 99    
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* The mean difference is significant at the 0.05 level.  
 
This shows that as the duration of cannabis abuse increases the mean scores 
of withdrawal symptoms also increases. 
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TABLE 19: 
COMPARISON OF DURATION OF ILLNESS WITH  
THE DURATION OF CANNABIS USE 
 
 
 
 
 
DURATION 
OF 
CANNABIS 
ABUSE 
N Mean 
Std.  
Deviation Std. Error 
95% Confidence  
Interval for Mean 
Lower Bound Upper Bound 
<5 YEARS 54 13.3241 10.96184 1.49172 10.3321 16.3161 
5-10 YEARS 26 25.1538 17.24805 3.38262 18.1872 32.1205 
ABOVE 10 
YEARS 
20 33.5750 39.03011 8.72740 15.3083 51.8417 
Total 100 20.4500 22.36345 2.23634 16.0126 24.8874 
ANOVA 
 
 Sum of 
Squares 
Df Mean 
Square 
F Sig. 
Between 
Groups 
6762.649 2 3381.325 7.672 .001 
Within Groups 42749.601 97 440.718   
Total 49512.250 99    
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CHART 13 
LINE CHART COMPARING THE DURATION OF CANNABIS ABUSE 
WITH THE DURATION OF ILLNESS PERIOD 
 
. 
The above table & chart shows that the duration of illness is directly 
proportional to the duration of cannabis abuse. As the duration of cannabis 
abuse increased, the duration illness also increased proportionately. 
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DISCUSSION 
Our study concluded that specific socio demographics were associated 
with cannabis use disorder. CUDs are more common in males. This is 
consistent with the various other studies. Though various studies state the 
prevalence of cannabis use in females was very much significant. In our study 
we found zero prevalence that may be due to subjective bias in our sampling 
technique. Secondly few studies highlighted that males were more likely to 
become cannabis dependent in early years after initial use.49 
In our study we found those who presented with cannabis related 
problems are predominantly males, 77% unmarried, 70% belong to urban area, 
96% belong to LSES, 64% employed. The mean age of onset of cannabis use 
was 18.36 years with a median of 17 years. This was approximately consistent 
with a similar study done in 2013 by Hercilio et al, which conclude those who 
were seeking treatment for CUD were 81% male, 66% single, 62.5% 
employed. The mean age of onset of use of cannabis was 16.53 years with 
standard deviation 4.66 years.44 
Regarding religion, 88% belong to Hinduism. This is most probably due 
to small sample size and also certain religion has restriction towards illicit 
substance use. 
Regarding education, 79% of people were below 10th standard. That too, 
most people were discontinued studies due to use of cannabis. In previous 
literature which evaluates the effects of cannabis on education, the most 
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important issue concerned is the risk of early drop outs from school due to 
heavy, regular use of cannabis. Hall et al specifically shown that use of 
cannabis produce impairment in reaction time, impairment in short term 
memory, loosening association and they become the reasons that cause 
impairment in attainment of proper education.50 
87% has family history of substance use disorder whereas history of 
mental illness present only in 13%. The strongest predictor for adolescent 
substance use is do their parents use substances or not. This is in accordance 
with social learning theory. Numerous studies found that substance use among 
parents greatly influences the onset of substance use by their children. Andrews 
et al in US did a study from which parent the children get the behavior. He 
suggested that the children get smoking behavior from their mother and 
drinking behavior from the father.51 
68% used cannabis in adolescent period i.e less than 19 years. This is 
consistent with previous studies by Fergusson et al, he concluded that 70% of 
cannabis users belong to the age group less than 21 years52. Similarly Poulton 
et al showed that 62% of cannabis users were less than 20 years53. 
In our study we found that 27% of cannabis users were violence prone, 
53% were impulsive, 32% has deviant behavior, 45% have drug using peers, 
and 33% admitted drug availability in neighborhood. This is consistent with the 
previous studies which conclude that cannabis use is more prevalent among 
young people who belong to disadvantaged family or social background, 
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people with adjustment problems, depression in early years, poor scholastic 
achievement, unemployment and those who were exposed to difficult 
childhood circumstances54. In our study also we found 79% quit studies below 
10th grade. 36% were unemployed, 96% belong to lower socioeconomic status, 
and 87% has family history of substance use disorder. By wrong role modeling 
they were prone to use of cannabis at early age. When we compared these 
psychosocial factors among adolescent onset cannabis user and adult onset 
cannabis users, (table 15) we found there was significantly high level of 
impulsivity, drug using peer relationship, drug availability in neighborhood, 
skipping at school or work were more among adolescent onset group. In a 
previous study also it showed that the violent / impulsive was moderately 
strongly associated with the use of cannabis at the age of 14-15 years. 
Thereafter decreases as age advances and less by the age 20-21 years.54 
Comorbid substance use among cannabis users: 
Our study showed that 48% use nicotine, 66% use alcohol and 27% use 
other psychoactive substance like fevibond, HANS, nitrazepam tablets, cough 
syrup etc. 84% of the sample use one or other psychoactive substance along 
with cannabis. 16% were only cannabis users. It has been found in various 
studies that use of cannabis increase the risk of developing other substance 
dependence. In 1970’s researchers debated about “the gateway hypothesis”  
that people who use illicit substances like heroin, cocaine would have been 
used initially one of the gateway drugs like tobacco, alcohol or cannabis. 
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(Vanyukov et al, 2012)55. Now researchers began to reveal reverse gateway 
hypothesis. In that they say use of cannabis is reverse gateway for the onset of 
other drugs like nicotine or alcohol (Agrawal et al 2008)56. Various studies and 
meta-analysis found that there was a moderate evidence of statistically 
significant association between the use of cannabis and the occurrence of other 
substance abuse or dependence which includes alcohol, tobacco and other illicit 
substances.57 
Similarly one follow up study done in united states revealed that those 
who used cannabis at initial phase later in 3 years found to around 3 times 
higher rate of alcohol abuse compared to individuals who did not used 
cannabis. Similarly the risk of abusing tobacco was also two times high among 
them. 
Psychiatric comorbidity among persons abusing cannabis: 
Our study found that 61% qualified for psychosis, 21% for non-alcohol 
psychoactive substance use disorders [cannabis use disorder], 11% as Mania, 
6% with antisocial personality disorder and 1% with depression. This was 
similar to the study done by Sarkar et al who found that 53% had psychotic 
illness and 34% had substance dependence45.  Similar study done in Brazil in 
2010 found that 22.5% had depression, 11% had generalized anxiety disorder, 
8.8% panic disorder, 8.8% had schizophrenia, and rest around 31% had only 
cannabis dependence44. 
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This study by Hercilio et al concluded that 61.2% had psychiatric 
comorbidity among cannabis dependent persons. Another study by Holscher et 
al showed 42% had comorbid psychiatric disorders. They also concluded that 
the most prevalent is depression and generalized anxiety disorders. But our 
findings were inconsistent with those results by concluding around 79% has 
comorbid psychiatric condition in that psychosis was predominant illness 
found58.  
This may be due to sampling error that we took sample in a tertiary care 
center where people with predominantly major mental illnesses report. This can 
be adjusted if we did our study at multicenter level / community level. Among 
psychotic patients, the average duration of psychotic illness was found to be 
24.98months. Cannabis induced transient psychotic illness would last only up 
to few months. (DSM V) This showed that use of cannabis has a contributing 
effect on the development of psychotic symptoms. Similarly, the Dutch study 
showed that people who are genetically vulnerable are at greater risk to develop 
psychosis than people without family history but abusing cannabis. The RD 
(risk difference) of cannabis use is 2.2% whereas those who have family 
history of psychosis are 54.7%.59 But in our study those who developed 
psychosis has family history of some mental illness only in about 16.4%. While 
nearly 83% had no history supportive of mental illness in their family. 
Four hypothesis were formulated by various studies for the associations 
of cannabis and psychosis. 
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1. Confounding hypothesis – By this, use of cannabis often mixed with 
the other substance use and various other factors that can cause 
psychosis. 
2. Interaction hypothesis – By this, cannabis as a component causing 
psychosis in vulnerable individuals. 
3. Reverse causality hypothesis – By this theory, they hypothesis that to 
cope with psychotic symptoms especially negative symptoms, people 
use cannabis. 
4. Ethological hypothesis – In this hypothesis, cannabis as a direct cause 
for psychotic symptoms.60 
Our study definitely ruled out reverse causality hypothesis since no one 
suffered from psychotic symptoms before the use of cannabis. But we could 
not conclude or exclude other hypothesis as follow up study will be needed to 
confirm causal association between the two. 
The average age of onset of psychotic symptoms was found to be about 
25.54years and the average durations of cannabis use among them was found 
as 7.15years. The mean age of onset of cannabis in psychotic group was found 
to be 18.36 years. One Swedish study found a relation of dose – response 
between the frequency of use of cannabis at the age of 18 and the risk of 
schizophrenia diagnosis over 15 year’s period61. In our study, we found use of 
cannabis over 7.15 years produced psychotic symptoms. 
Though, DSM 5 did not mention about cannabis induced mood disorder, 
in our study we found around 11% of persons abusing cannabis suffer from 
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Mania. In a study done by Gilbert et al found that use of cannabis was 
associated with a nearly 3 fold increase in symptoms by the odds ratio 
compared with clinical outcome32. 
Another study done in Italy suggested that the less realistic in thinking 
and more involvement in religion and spiritual experience are at higher risk of 
developing cannabis dependence. They also found that the following 
psychiatric disorders occur as Axis I comorbidity – Adjustment disorder, 
Dysthymia, Major depression, GAD. They showed certain personality 
disorders specifically associated with the use of cannabis i.e. borderline, 
histrionic, dependent and unspecified5. 
People without comorbid psychiatric illness report that they use 
cannabis or other drugs for external reasons such as problems at work, social 
pressure, peer pressure etc. 
We found only 1% in our study sample reported as depression. Various 
studies also provide mixed evidence upon the associative nature of the use of 
cannabis and depression. Brook et al in a cohort study found that use of 
cannabis early i.e. before 20 years was associated with mild increase in the risk 
of MDD by 27 years of age. But after the control of confounding factors like 
demographics, history of depression in the family, childhood depression, and 
the odds ratio was 1.7, that is people who use cannabis has 1.7 times higher risk 
in developing MDD compared with those who did not use cannabis. But by the 
age of 27 years the risk of developing depression become very less62. 
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 Similar result was also given by Fergusson et al, in which the 
association between the use of cannabis and the depressive disorder with the 
age, by the age of 20-21 years, significantly there was no association between 
the two. Since the average age at presentation of our sample was around 25 
years, the risk of depression may be low comparing the results of the 
abovementioned studies.63 
About withdrawal symptoms, the common symptoms we encountered 
were craving for cannabis, easy irritability, anger outbursts. On Likert scale, 
the average value for cannabis withdrawal symptoms was found to be 14.02 out 
of maximum score of 190. And also it has been found the mean of withdrawal 
score increases significantly as the duration of cannabis use increases (Table 
17). This is consistent with the finding of a study published in the Journal of 
clinical psychiatry by Deborah et al64. 
Another study done by Bonnet et al also suggested that 75% of people 
who abuse cannabis seeking outpatient treatment usually develop mild to 
moderate cannabis withdrawal symptoms. Heavy and prolonged use favors the 
increased risk of CWS65. 
Hofler et al in 1999 did a study on risk factors for cannabis use among 
1228 subjects. The risk factors that were well documented are drug use in peer 
group, drug availability in immediate neighborhood, low competence and self-
esteem. In addition, they found substance use disorder in family and experience 
with legal drugs before the use of cannabis play an important role among 14-17 
years old subjects who use cannabis.66 
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CONCLUSION 
 
• Psychiatric comorbidity is a common occurrence in persons with cannabis 
dependence especially those seek treatment. 
• Psychotic disorders are the most common presentation presented in a 
tertiary care center. 
• Cannabis withdrawal symptoms increase as the duration of cannabis abuse 
increase. 
• Comorbid other substance use and family history of substance use are the 
commonest association with the persons who abuse cannabis. 
• Adolescents who begin to use cannabis has poor psychosocial factors like 
high levels of impulsivity, drug using peer relationship drug availability in 
neighborhood, skipping at school or work than those begin to use 
cannabis in early adulthood.  
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STRENGTH OF THE STUDY 
• The sample taken according to the sample size calculation. 
• The tools used were validated and has good internal consistency. 
• This study conducted in a tertiary care center replicated the findings of 
previous studies.  
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LIMITATIONS 
 
1. The cross sectional study design used in our study can be helpful to study 
the association between variables but it could not assess causal 
relationship. 
2. As this study has been done in a tertiary care setting, burden in a 
community level could not be generalized. 
3. The amount and pattern of cannabis use were not considered in our study. 
4. Often associated with the comorbid alcohol use, that may have a 
confounding effect. 
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FUTURE DIRECTIONS 
 
1. Community level study will be needed to assess the exact prevalence of 
cannabis use disorders and the distribution of psychiatric comorbidity. 
2. Comparison between cannabis dependent persons with or without comorbid 
mental illness, will throw added insight upon the biopsychosocial  causes 
for psychiatric comorbidity.  
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INFORMATION TO PARTICIPANTS 
 
Title : “ EVALUATION OF PSYCHOSOCIAL FACTORS AND PSYCHIATRIC COMORBIDITY AMONG 
PERSONS ABUSING CANNABIS ” 
Principal Investigator :                             Dr. S.DEEPA, 
                                                                 II Year, MD Psychiatry Post Graduate, 
                                                                Madras Medical College, Chennai. 
Co-Investigator (if any) : 
Name of Participant : 
Site : IMH, MMC, Chennai. 
You are invited to take part in this research. The information in this document is meant to help 
you decide whether or not to take part. Please feel free to ask if you have any queries or 
concerns. 
What is the purpose of research? 
Cannabis abuse is a common disorder characterized by significant impairment of functioning in 
day to day life. Depression and psychosis occur in a substantial proportion of cannabis abuse 
patients, thereby increasing the burden. We want to find out how commonly clinical depression 
and psychosis occurs in patients with cannabis abuse. 
We have obtained permission from the Institutional Ethics Committee. 
The study design 
You will be interviewed while you are attending our hospital. 
Study procedures 
The study involves evaluation for the presence of depression and / or psychosis for which we 
will be interviewing you with various questionnaires. You will be required to spare roughly half 
an hour for a one-time interview during your visit to the hospital. 
Possible benefits to you 
If you are found to have depression and / or psychosis you will be referred to the Psychiatry OP, 
IMH for further management of these conditions (s). 
Possible benefits to other people 
The results of the research may provide benefits to the society in terms of advancement of 
medical knowledge and / or therapeutic benefit to future patients. 
Confidentially of the information obtained from you 
You have the right to confidentially regarding the privacy of your medical information (personal 
details, results of physical examinations, investigations, and your medical history). By signing 
this document, you will be allowing the research team investigations, other study personnel and 
the Institutional Ethics Committee, to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or your 
relationship with the investigator or the institution. You will be taken care of and you will not 
lose any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw from 
this study at any time during the course of the study without giving any reasons. However, it is 
advisable that you talk to the research team prior to stopping the treatment / discontinuing of 
procedures etc. 
 
 
Signature of Investigator                                               Signature of Participant 
Date :                                                                                       Date : 
 
 
INFORMED CONSENT FORM 
Title : : “ EVALUATION OF PSYCHOSOCIAL FACTORS AND PSYCHIATRIC COMORBIDITY AMONG PERSONS 
ABUSING CANNABIS ” 
Name of the Participant : 
Name of Principal/Co-Investigator : Dr. S.DEEPA, 
Name of Institution : IMH, MMC, Chennai. 
Name and address of the sponsor / agency(ies), if any: _________________ 
I __________________(name of participant), have read the information in this form (or it has been read 
to me). I was free to ask any questions and they have been answered. I am exercising my free power of 
choice, hereby give my consent to be included as a participant in “EVALUATION OF PSYCHOSOCIAL 
FACTORS AND PSYCHIATRIC COMORBIDITY AMONG PERSONS ABUSING CANNABIS ” 
1) I have read and understood this consent form and the information provided to me. 
2) I have had the consent document explained to me. 
3) I have been explained about the nature of the study. 
4) I have been explained about my rights and responsibilities by the investigator. 
5) I have informed the investigator of all the treatments I am taking or have taken in the past, including 
any native (alternative) treatments. 
6) I am aware of the fact that I can opt out of the study at any time without having to give any reason 
and this will not affect my future treatment in the hospital. 
7) I hereby give permission to the investigators to release the information obtained from me as a result 
of participation in this study to the regulatory authorities, Government agencies, and ethics committee. 
Iunderstand that they may inspect my original records. 
8) I understand that my identity will be kept confidential if my data are publicly presented. 
9) I have had my questions answered to my satisfaction. 
10) I consent voluntarily to participate as a participant in the research study. 
I am aware, that I can opt out of the study, I should contact the investigators. By signing this consent 
from, I attest that the information given in this document has been clearly explained to me and 
understood by me. I will be given a copy of this consent document. 
For adult participants 
Name and signature / thumb impression of the participant (or legal representative if participant is 
incompetent): 
(Name)____________________________(Signature)___________________Date:__________ 
Name and signature of impartial witness (required for illiterate patients): 
(Name)____________________________(Signature)___________________Date:__________ 
Address and contact number of the impartial witness:_______________________ 
Name and signature of the investigator or his representative obtaining consent: 
(Name)________________________ (Signature) ___________________Date:__________ 
  
SOCIO DEMOGRAPHIC PROFILE 
Name: 
Age: 
Sex: 
Education: 
Occupation: 
Income:  
Marital status: 
Place: rural/ urban/semi urban 
Socio economic status: 
Religion: 
PSYCHO SOCIAL FACTORS: 
Personal attributes: 1. Ego integration 2. Violence towards others 3.Psychological symptoms 4. 
Impulsivity 
Marital relationship: 1. Satisfaction with partner 2.marital harmony 3.arguements with partner 
Peer relationship: 1. Deviance 2. Illegal drug use 3. Association with drug using peers 
Neighborhood: 1. Drug offering 2. Violence toward subject 3.Drug availability 
Work: 1. Skipped work 2. Work achievement 
Substance use:
 
 1. Nicotine 2. Alcohol  3. others 
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Section IV. Getting Started
Explain and Ask Client To Complete Marijuana Problem Scale; Evaluate
Consequences of Marijuana Use
The Marijuana Problem Scale (MPS) (form AS5), developed by Stephens and colleagues (1994a),
is a self-report assessment that helps the client identify areas in his or her life affected by
marijuana use. It contains 19 items that represent potential negative effects of marijuana on
social relationships, self-esteem, motivation and productivity, work and finances, physical health,
memory impairment, and legal problems. The items were chosen based on existing self-report
drug abuse severity measures and on data from people who sought treatment for marijuana use. 
Some questions on the MPS are similar to those in the SCID-IV. However, the MPS is a self-report
instrument and the counselor should not base diagnostic decisions on the MPS alone. Clinical
judgment is needed to make a diagnosis of cannabis abuse. 
The counselor gives the form to the client and instructs the client to take a few moments to
respond to each item by indicating whether he or she experienced a particular problem related to
marijuana use in the past month. After reading each question, the client circles the corresponding
number on the questionnaire:
Not a problem (0) A minor problem (1) A serious problem (2).
After answering all the questions, the client gives the form back to the counselor who counts the
number of items identified as either minor or serious problems. Higher scores generally indicate
more serious problems with marijuana. However, it is important to review the specific problem
items with clients because the nature of the problems reported may be more important than the
total score. For instance, although nearly all people who use marijuana and seek treatment report
feeling bad about their use, a smaller number will indicate serious problems with friends, family,
work, or finances. Exhibit VII-1 in section VII presents the frequency of problems reported by MTP
participants. 
The counselor keeps the form and uses the information to complete the client’s PFR, which is
discussed in the next session. 
Administer Reasons for Quitting Questionnaire; Evaluate Reasons for 
Seeking Treatment
The Reasons for Quitting Questionnaire (form AS6) is based on earlier work with tobacco
cessation and has been modified based on initial results with people who use marijuana and seek
treatment (McBride et al. 1994). The 26 items assess reasons for quitting marijuana in the
following broad categories: health concerns, desire for self-control, and social and legal
influences. The counselor gives the client the form and asks him or her to take a few moments to
indicate the degree to which each reason applies to him or her using a 5-point scale:
Not at all (0) A little bit (1) Moderately (2) Quite a bit (3) Very much (4).
Following are different types of problems you may have experienced as a result of smoking
marijuana. Please circle the number that indicates whether each item has been a problem for you
in the past month.
Marijuana Problem Scale
Form AS5
Has marijuana use caused you… NoProblem
Serious
Problem
Minor
Problem
1. Problems between you and your partner 0 1 2
2. Problems in your family 0 1 2
3. To neglect your family 0 1 2
4. Problems between you and your friends 0 1 2
5. To miss days at work or miss classes 0 1 2
6. To lose a job 0 1 2
7. To have lower productivity 0 1 2
8. Medical problems 0 1 2
9. Withdrawal symptoms 0 1 2
10. Blackouts or flashbacks 0 1 2
11. Memory loss 0 1 2
12. Difficulty sleeping 0 1 2
13. Financial difficulties 0 1 2
14. Legal problems 0 1 2
15. To have lower energy level 0 1 2
16. To feel bad about your use 0 1 2
17. Lowered self-esteem 0 1 2
18. To procrastinate 0 1 2
19. To lack self-confidence 0 1 2
1 of 2
To obtain the Marijuana Problem Scale (MPS) Score, add the number of items reported as either
a minor problem or serious problem. This score is used in the Personal Feedback Report (form
AS8) and compared with the scores in table C at the end of the instructions for creating the PFR.
Items circled as 1 or 2 by the client should be checked on part II of the Personal Feedback Report
(form AS8).
For Office Use
MPS Score: _____
Marijuana Problem Scale Scoring Instructions
Marijuana Problem Scale (continued)
Form AS5
2 of 2
The Cannabis Withdrawal Scale
Instructions: This version of the CWS asks about symptoms experienced over the last 24 hours, 
and can be administered by an interviewer OR by self report.
The following statements describe how you have felt over the last 24 hours. Please circle the 
number that most closely represents your personal experiences for each statement. For each 
statement, please rate its negative impact on normal daily activities on the same scale  
(0 = Not at all to 10 = Extremely), writing the number in the right hand column. 
 Not at all Moderately Extremely
Negative
Impact on  
daily activity
(0 – 10)
1 The only thing I could think about 
was smoking some cannabis 0 1 2 3 4 5 6 7 8 9 10
2 I had a headache 0 1 2 3 4 5 6 7 8 9 10
3 I had no appetite 0 1 2 3 4 5 6 7 8 9 10
4 I felt nauseous (like vomiting) 0 1 2 3 4 5 6 7 8 9 10
5 I felt nervous 0 1 2 3 4 5 6 7 8 9 10
6 I had some angry outbursts 0 1 2 3 4 5 6 7 8 9 10
7 I had mood swings 0 1 2 3 4 5 6 7 8 9 10
8 I felt depressed 0 1 2 3 4 5 6 7 8 9 10
9 I was easily irritated 0 1 2 3 4 5 6 7 8 9 10
10 I had been imagining being stoned 0 1 2 3 4 5 6 7 8 9 10
11 I felt restless 0 1 2 3 4 5 6 7 8 9 10
12 I woke up early 0 1 2 3 4 5 6 7 8 9 10
13 I had a stomach ache 0 1 2 3 4 5 6 7 8 9 10
14 I had nightmares and/or strange 
dreams 0 1 2 3 4 5 6 7 8 9 10
15 Life seemed like an uphill struggle 0 1 2 3 4 5 6 7 8 9 10
16 I woke up sweating at night 0 1 2 3 4 5 6 7 8 9 10
17 I had trouble getting to sleep  
at night 0 1 2 3 4 5 6 7 8 9 10
18 I felt physically tense 0 1 2 3 4 5 6 7 8 9 10
19 I had hot flashes 0 1 2 3 4 5 6 7 8 9 10
Score by summing each items value to a maximum withdrawal score of 190 (you can derive two 
scores from the scale: one for withdrawal intensity and one for the negative impact of withdrawal 
– each separate score has a theoretical maximum of 190).
Allsop, D., Norberg, M., Copeland, J., Fu, S. & Budney, A.J. (2011). The Cannabis Withdrawal Scale Development: 
Patterns and Predictors of Cannabis Withdrawal and Distress. Drug and Alcohol Dependence 119 (1-2), 123-129
Correspondence concerning this article should be addressed to Jan Copeland, National Cannabis Prevention  
and Information Centre, University of New South Wales, Sydney, Australia 2031. Phone: +61 2 9385 0231 
E-mail: j.copeland@unsw.edu.au
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Patient Name: Patient Number:  
Date of Birth:  Time Interview Began:  
Interviewer’s Name: Time Interview Ended:  
Date of Interview:  Total Time:  
    
 
  MEETS 
 MODULES TIME FRAME CRITERIA DSM-IV ICD-10 
 
A MAJOR DEPRESSIVE EPISODE Current (2 weeks)   296.20-296.26  Single F32.x  S 
  Recurrent   296.30-296.36  Recurrent F33.x  S  
   
 MDE WITH MELANCHOLIC FEATURES Current (2 weeks)   296.20-296.26  Single F32.x  S 
 Optional    296.30-296.36  Recurrent F33.x  S 
 
B DYSTHYMIA Current (Past 2 years)   300.4  F34.1  S 
 
C SUICIDALITY Current (Past Month)       S 
  Risk:  Low   Medium   High 
 
D MANIC EPISODE Current   296.00-296.06  F30.x-F31.9 S 
  Past   
 HYPOMANIC EPISODE Current   296.80-296.89  F31.8-F31.9/F34.0 S 
  Past   
 
E PANIC DISORDER Current (Past Month)   300.01/300.21  F40.01-F41.0 S 
  Lifetime   
 
F AGORAPHOBIA Current   300.22  F40.00 S 
 
G SOCIAL PHOBIA (Social Anxiety Disorder) Current (Past Month)   300.23  F40.1  S 
 
H OBSESSIVE-COMPULSIVE DISORDER Current (Past Month)   300.3  F42.8  S 
 
I POSTTRAUMATIC STRESS DISORDER Current (Past Month)   309.81  F43.1  S 
  
J ALCOHOL DEPENDENCE Past 12 Months   303.9  F10.2x S 
 ALCOHOL ABUSE Past 12 Months   305.00  F10.1  S  
 
K SUBSTANCE DEPENDENCE (Non-alcohol) Past 12 Months   304.00-.90/305.20-.90 F11.1-F19.1 S 
 SUBSTANCE ABUSE (Non-alcohol) Past 12 Months   304.00-.90/305.20-.90 F11.1-F19.1 S 
 
L PSYCHOTIC DISORDERS Lifetime   295.10-295.90/297.1/ F20.xx-F29 S 
  Current   297.3/293.81/293.82/ 
     293.89/298.8/298.9 
  
MOOD DISORDER WITH PSYCHOTIC FEATURES Lifetime   296.24/296.34/296.44         F32.3/F33.3/ S              
 Current    296.24/296.34/296.44      F30.2/F31.2/F31.5   
                                   F31.8/F31.9/F39 S  
   
M ANOREXIA NERVOSA Current (Past 3 Months)  307.1  F50.0  S 
 
N BULIMIA NERVOSA Current (Past 3 Months)  307.51  F50.2  S 
 
 ANOREXIA NERVOSA, BINGE EATING/PURGING TYPE Current   307.1  F50.0  S 
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O GENERALIZED ANXIETY DISORDER Current (Past 6 Months)  300.02  F41.1  S 
 
P ANTISOCIAL PERSONALITY DISORDER Lifetime   301.7  F60.2  S 
 Optional 
 
 Which problem troubles you the most?  Indicate your response by checking the appropriate check box(es).  
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GENERAL INSTRUCTIONS 
 
 
The M.I.N.I. was designed as a brief structured interview for the major Axis I psychiatric disorders in DSM-IV and ICD-10.  
Validation and reliability studies have been done comparing the M.I.N.I. to the SCID-P for DSM-III-R and the CIDI (a structured 
interview developed by the World Health Organization for lay interviewers for ICD-10).  The results of these studies show that the 
M.I.N.I. has acceptably high validation and reliability scores, but can be administered in a much shorter period of time (mean 18.7 ± 
11.6 minutes, median 15 minutes) than the above referenced instruments.  It can be used by clinicians, after a brief training session.  
Lay interviewers require more extensive training. 
 
INTERVIEW: 
 In order to keep the interview as brief as possible, inform the patient that you will conduct a clinical interview that is more 
structured than usual, with very precise questions about psychological problems which require a yes or no answer. 
 
GENERAL FORMAT: 
 The M.I.N.I. is divided into modules identified by letters, each corresponding to a diagnostic category. 
 •At the beginning of each diagnostic module (except for psychotic disorders module), screening question(s) corresponding to 
the main criteria of the disorder are presented in a gray box. 
 •At the end of each module, diagnostic box(es) permit the clinician to indicate whether diagnostic criteria are met. 
 
CONVENTIONS: 
Sentences written in « normal font » should be read exactly as written to the patient in order to standardize the assessment of 
diagnostic criteria. 
 
Sentences written in « CAPITALS » should not be read to the patient.  They are instructions for the interviewer to assist in the 
scoring of the diagnostic algorithms. 
 
Sentences written in « bold » indicate the time frame being investigated.  The interviewer should read them as often as 
necessary.  Only symptoms occurring during the time frame indicated should be considered in scoring the responses. 
 
Answers with an arrow above them (·) indicate that one of the criteria necessary for the diagnosis(es) is not met. In this 
case, the interviewer should go to the end of the module, circle « NO » in all the diagnostic boxes and move to the next 
module. 
 
When terms are separated by a slash (/) the interviewer should read only those symptoms known to be present in the patient  
(for example, question H6). 
 
Phrases in (parentheses) are clinical examples of the symptom.  These may be read to the patient to clarify the question. 
 
RATING INSTRUCTIONS: 
 
All questions must be rated. The rating is done at the right of each question by circling either Yes or No.  Clinical judgment 
by the rater should be used in coding the responses.  The rater should ask for examples when necessary, to ensure accurate 
coding.  The patient should be encouraged to ask for clarification on any question that is not absolutely clear. 
 
The clinician should be sure that each dimension of the question is taken into account by the patient (for example, time 
frame, frequency, severity, and/or alternatives). 
Symptoms better accounted for by an organic cause or by the use of alcohol or drugs should not be coded positive in the 
M.I.N.I.  The M.I.N.I. Plus has questions that investigate these issues. 
 
For any questions, suggestions, need for a training session, or information about updates of the M.I.N.I., please contact : 
 
David V Sheehan, M.D., M.B.A.  Yves Lecrubier, M.D. / Thierry Hergueta, M.S.  
University of South Florida College of Medicine  INSERM U302  
3515 East Fletcher Avenue  Hôpital de la Salpétrière  
Tampa, FL USA 33613-4788  47, boulevard de l’Hôpital  
tel : +1 813 974 4544;  fax : +1 813 974 4575  F. 75651 PARIS, FRANCE   
e-mail : dsheehan@hsc.usf.edu  tel : +33 (0) 1 42 16 16 59;  fax : +33 (0) 1 45 85 28 00  
  e-mail : hergueta@ext.jussieu.fr 
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A.  MAJOR DEPRESSIVE EPISODE 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
A1  Have you been consistently depressed or down, most of the day, nearly  NO YES  
  every day, for the past two weeks? 
 
A2  In the past two weeks, have you been much less interested in most things or  NO YES  
  much less able to enjoy the things you used to enjoy most of the time? 
   ·  
  IS A1 OR A2 CODED YES? NO YES 
 
A3  Over the past two weeks, when you felt depressed or uninterested: 
 
 a Was your appetite decreased or increased nearly every day?  Did your weight  NO YES *  
  decrease or increase without trying intentionally (i.e., by ±5% of body weight 
  or ±8 lbs. or ±3.5 kgs., for a 160 lb./70 kg. person in a month)?   
  IF YES TO EITHER, CODE YES. 
 
 b Did you have trouble sleeping nearly every night (difficulty falling asleep, waking up  NO YES  
  in the middle of the night, early morning wakening or sleeping excessively)? 
 
 c Did you talk or move more slowly than normal or were you fidgety, restless NO YES *  
  or having trouble sitting still almost every day? 
 
 d Did you feel tired or without energy almost every day? NO YES  
 
 e Did you feel worthless or guilty almost every day? NO YES  
  
 f Did you have difficulty concentrating or making decisions almost every day? NO YES  
 
 g Did you repeatedly consider hurting yourself, feel suicidal, or wish that you were dead?  NO YES  
   
  
  
            ARE 5 OR MORE ANSWERS (A1-A3) CODED YES?  
 
  NO                        YES * 
 
MAJOR DEPRESSIVE 
EPISODE, CURRENT    
 
 
IF PATIENT HAS CURRENT MAJOR DEPRESSIVE EPISODE CONTINUE TO A4,  
OTHERWISE MOVE TO MODULE B: 
            · 
A4 a During your lifetime, did you have other episodes of two weeks or more when you felt  NO YES  
  depressed or uninterested in most things, and had most of the problems we just talked about? 
 
 
 
b   In between 2 episodes of depression, did you ever have an interval                                  
of at least 2 months, without any depression and any loss of interest? 
         
 
 
 
 
  NO                         YES 
 
MAJOR DEPRESSIVE 
EPISODE, RECURRENT  
 
 
 
*  If patient has Major Depressive Episode, Current, use this information in coding the corresponding questions on page 5 (A6d, 
A6e). 
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 MAJOR DEPRESSIVE EPISODE WITH MELANCHOLIC FEATURES (optional) 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
IF THE PATIENT CODES POSITIVE FOR A CURRENT MAJOR DEPRESSIVE EPISODE (A3 = YES), EXPLORE THE FOLLOWING:  
 
 
A5 a During the most severe period of the current depressive episode, did you lose almost NO YES  
  completely your ability to enjoy nearly everything? 
 
 b During the most severe period of the current depressive episode,  NO YES  
  did you lose your ability to respond to things that previously gave  
  you pleasure, or cheered you up?  
  IF NO: When something good happens does it fail to make you feel better, even temporarily?  
 
 · 
  IS EITHER A5a OR A5b CODED YES? NO YES  
 
   
A6  Over the past two week period, when you felt depressed and uninterested: 
 
 a Did you feel depressed in a way that is different from the kind of feeling  NO YES  
  you experience when someone close to you dies? 
 
 b Did you feel regularly worse in the morning, almost every day? NO YES  
 
 c Did you wake up at least 2 hours before the usual time of awakening and  NO YES  
  have difficulty getting back to sleep, almost every day? 
 
 d IS A3c CODED YES (PSYCHOMOTOR RETARDATION OR AGITATION)? NO YES  
 
 e IS A3a CODED YES FOR ANOREXIA OR WEIGHT LOSS? NO YES  
 
 f Did you feel excessive guilt or guilt out of proportion to the reality of the situation? NO YES  
   
 
  
  
               ARE 3 OR MORE A6 ANSWERS CODED YES?      
                
     
    NO                                YES 
 
Major Depressive Episode 
with 
Melancholic Features 
                  Current 
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B.  DYSTHYMIA 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
IF PATIENT'S SYMPTOMS CURRENTLY MEET CRITERIA FOR MAJOR DEPRESSIVE EPISODE, DO NOT EXPLORE THIS MODULE. 
 
   · 
B1  Have you felt sad, low or depressed most of the time for the last two years? NO YES  
 
    · 
B2  Was this period interrupted by your feeling OK for two months or more? NO YES  
 
B3  During this period of feeling depressed most of the time: 
 
 a Did your appetite change significantly? NO YES  
 
 b Did you have trouble sleeping or sleep excessively? NO YES  
 
 c Did you feel tired or without energy? NO YES  
 
 d Did you lose your self-confidence? NO YES  
 
 e Did you have trouble concentrating or making decisions? NO YES  
 
 f Did you feel hopeless? NO YES  
   ·  
  ARE 2 OR MORE B3 ANSWERS CODED YES? NO YES 
 
  
  
B4         Did the symptoms of depression cause you significant distress or impair 
               your ability to function at work, socially, or in some other important way? 
 
             
            
 
  NO                          YES 
 
DYSTHYMIA 
CURRENT 
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C.  SUICIDALITY 
 
 
  In the past month did you: 
                    Points 
C1  Suffer any accident? NO YES 0 
  IF NO TO C1, SKIP TO C2; IF YES, ASK C1a,: 
C1a  Plan or intend to hurt yourself in that accident either passively or actively? NO YES 0 
  IF NO TO C1a, SKIP TO C2: IF YES, ASK C1b,: 
C1b  Did you intend to die as a result of this accident? NO YES 0 
 
C2  Think that you would be better off dead or wish you were dead? NO YES 1 
 
C3  Want to harm yourself or to hurt or to injure yourself? NO YES 2 
 
C4  Think about suicide? NO YES 6 
 
IF YES, ASK ABOUT THE INTENSITY AND FREQUENCY OF THE SUICIDAL IDEATION: 
 
Frequency                                   Intensity 
 
Occasionally     S          Mild            S        Can you control these impulses 
Often      S              Moderate     S  and state that you will not act 
Very often        S                   Severe        S  on them while in this program?    
       Only score 8 points if response is NO. NO YES    8  
         
C5  Have a suicide plan?  NO YES 8 
 
C6  Take any active steps to prepare to injure yourself or to prepare for a suicide attempt  
  in which you expected or intended to die? NO YES 9 
 
C7  Deliberately injure yourself without intending to kill yourself? NO YES 4 
 
C8  Attempt suicide?   NO YES 10 
 Hoped to be rescued / survive      S  
 Expected / intended to die            S 
 
  In your lifetime: 
 
C9  Did you ever make a suicide attempt? NO YES 4 
 
  
    IS AT LEAST 1 OF THE ABOVE (EXCEPT C1) CODED YES? 
 
 
 
                   IF YES, ADD THE TOTAL NUMBER OF POINTS FOR THE ANSWERS (C1-C9)  
CHECKED ‘YES’ AND SPECIFY THE LEVEL OF SUICIDE RISK AS                                    
INDICATED IN THE DIAGNOSTIC BOX: 
                    
 
   MAKE ANY ADDITIONAL COMMENTS ABOUT YOUR ASSESSMENT  
  OF THIS PATIENT’S CURRENT AND NEAR FUTURE SUICIDE RISK IN  
  THE SPACE BELOW: 
            
 
  NO                           YES 
 
SUICIDE  RISK 
CURRENT 
 
   1-8 points     Low               S 
   9-16 points   Moderate       S 
   > 17 points   High              S 
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D. (HYPO) MANIC EPISODE 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
 
D1 a Have you ever had a period of time when you were feeling 'up' or 'high' or ‘hyper’                      NO       YES   
  or so full of energy or full of yourself that you got into trouble, or that 
  other people thought you were not your usual self?  (Do not consider 
  times when you were intoxicated on drugs or alcohol.) 
 
  IF PATIENT IS PUZZLED OR UNCLEAR ABOUT WHAT YOU MEAN  
  BY 'UP' OR 'HIGH' OR ‘HYPER’, CLARIFY AS FOLLOWS:   By 'up' or 'high' or ‘hyper’  
  I mean: having elated mood; increased energy; needing less sleep; having rapid  
  thoughts; being full of ideas; having an increase in productivity,  
  motivation, creativity, or impulsive behavior. 
 
  IF NO, CODE NO TO D1b:  IF YES ASK: 
 
 b Are you currently feeling ‘up’ or ‘high’ or ‘hyper’ or full of energy?                                                 NO YES   
 
D2 a Have you ever been persistently irritable, for several days, so that you                                      NO       YES   
  had arguments or verbal or physical fights, or shouted at people outside 
  your family?  Have you or others noticed that you have been more irritable 
  or over reacted, compared to other people, even in situations that you felt 
  were justified? 
 
  IF NO, CODE NO TO D2b:  IF YES ASK: 
 
 b Are you currently feeling persistently irritable?                                                                      NO YES   
   · 
  IS D1a OR D2a CODED YES?  NO YES 
 
 
D3  IF D1b OR D2b = YES: EXPLORE THE CURRENT AND THE MOST SYMPTOMATIC PAST EPISODE, OTHERWISE 
  IF D1b AND D2b = NO: EXPLORE ONLY THE MOST SYMPTOMATIC PAST EPISODE 
 
 During the times when you felt high, full of energy, or irritable did you: 
   Current Episode Past Episode 
 
 a Feel that you could do things others couldn't do, or that you were an NO YES NO YES  
  especially important person?   
  IF YES, ASK FOR EXAMPLES. 
  THE EXAMPLES ARE CONSISTENT WITH A DELUSIONAL IDEA.     S No      S Yes 
 
 b Need less sleep (for example, feel rested after only a few hours sleep)? NO YES NO YES  
 
 c Talk too much without stopping, or so fast that people had difficulty NO YES NO YES  
  understanding? 
 
 d Have racing thoughts? NO YES  NO YES   
 
 e Become easily distracted so that any little interruption could distract you? NO YES NO YES  
 
 f Become so active or physically restless that others were worried about you? NO YES NO YES  
 
 g Want so much to engage in pleasurable activities that you ignored the risks or NO YES NO YES  
  consequences (for example, spending sprees, reckless driving, or sexual  
  indiscretions)? 
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   Current Episode Past Episode 
 
     · 
D3 (SUMMARY):  ARE 3 OR MORE D3 ANSWERS CODED YES  NO YES NO YES 
  (OR 4 OR MORE  IF D1a IS NO (IN RATING PAST EPISODE) AND D1b IS NO (IN RATING CURRENT EPISODE)?     
  RULE:  ELATION/EXPANSIVENESS REQUIRES ONLY THREE D3 SYMPTOMS WHILE  
  IRRITABLE MOOD ALONE REQUIRES 4 OF THE D3 SYMPTOMS. 
 
  VERIFY IF THE SYMPTOMS OCCURRED DURING THE SAME TIME PERIOD. 
 
D4  Did these symptoms last at least a week and cause significant problems at home,    NO          YES          NO          YES 
    at work, socially, or at school, or were you hospitalized for these  problems?  
   ↓ ↓           ↓        ↓  
  
   THE EPISODE EXPLORED WAS A:             S       S           S        S 
HYPOMANIC      MANIC              HYPOMANIC    MANIC 
EPISODE            EPISODE           EPISODE           EPISODE 
 
 
  
     IS D4 CODED NO? 
 
             
     
               SPECIFY IF THE EPISODE IS CURRENT OR PAST. 
 
     NO                       YES 
 
HYPOMANIC EPISODE 
 
CURRENT                 S  
PAST                       S   
 
 
  
             IS D4 CODED YES? 
            
            
 
               SPECIFY IF THE EPISODE IS CURRENT OR PAST. 
 
     NO                       YES 
 
MANIC EPISODE 
 
CURRENT                 S  
PAST                       S   
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E.  PANIC DISORDER 
 
(· MEANS :  CIRCLE NO IN E5, E6 AND E7 AND  SKIP TO F1) 
 
   · 
E1 a Have you, on more than one occasion, had spells or attacks when you suddenly NO YES  
  felt anxious, frightened, uncomfortable or uneasy, even in situations where most 
  people would not feel that way?   
   · 
 b Did the spells surge to a peak within 10 minutes of starting? NO YES  
  
   
   · 
E2  At any time in the past, did any of those spells or attacks come on unexpectedly NO YES  
or occur in an unpredictable or unprovoked manner? 
 
E3 Have you ever had one such attack followed by a month or more of persistent   NO YES  
concern about having another attack, or worries about the consequences of the attack 
or did you make a significant change in your behavior because of the attacks (e.g., shopping 
only with a companion, not wanting to leave your house, visiting the emergency 
room repeatedly, or seeing your doctor more frequently because of the symptoms?   
 
E4  During the worst spell that you can remember: 
   
 a Did you have skipping, racing or pounding of your heart? NO YES  
   
 b Did you have sweating or clammy hands? NO YES  
   
 c Were you trembling or shaking? NO YES  
 
 d Did you have shortness of breath or difficulty breathing? NO YES  
   
 e Did you have a choking sensation or a lump in your throat? NO YES  
   
 f Did you have chest pain, pressure or discomfort? NO YES  
   
 g Did you have nausea, stomach problems or sudden diarrhea? NO YES  
   
 h Did you feel dizzy, unsteady, lightheaded or faint? NO YES  
   
 i Did things around you feel strange, unreal, detached or unfamiliar, or did  NO YES  
you feel outside of or detached from part or all of your body? 
   
 j Did you fear that you were losing control or going crazy? NO YES  
   
 k Did you fear that you were dying? NO YES  
  
 l Did you have tingling or numbness in parts of your body? NO YES  
   
 m Did you have hot flushes or chills? NO YES  
   
E5  ARE BOTH E3, AND 4 OR MORE E4 ANSWERS, CODED YES? NO YES 
  PANIC DISORDER 
LIFETIME 
IF YES TO E5, SKIP TO E7. 
   
 
E6  IF E5 = NO, ARE ANY E4 ANSWERS CODED YES? NO YES  
    LIMITED SYMPTOM 
    ATTACKS LIFETIME 
  THEN SKIP TO F1.   
 
E7  In the past month, did you have such attacks repeatedly (2 or more) followed by  NO YES  
 persistent concern about having another attack?  PANIC DISORDER 
    CURRENT 
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F.  AGORAPHOBIA 
 
 
F1  Do you feel anxious or uneasy in places or situations where you might have a panic attack NO YES  
  or the panic-like symptoms we just spoke about, or where help might not be available or 
  escape might be difficult: like being in a crowd, standing in a line (queue),  
  when you are alone away from home or alone at home, or when crossing a bridge,  
  traveling in a bus, train or car? 
 
 
  IF F1 = NO, CIRCLE NO IN  F2. 
 
F2  Do you fear these situations so much that you avoid them, or suffer NO YES  
  through them, or need a companion to face them?             AGORAPHOBIA                    CURRENT  
 
 
  
  IS F2 (CURRENT AGORAPHOBIA) CODED NO   
               
                     and 
               
                 IS E7 (CURRENT PANIC DISORDER) CODED YES? 
 
 
 
     NO                      YES 
 
PANIC DISORDER 
without Agoraphobia 
CURRENT 
 
 
  
  IS F2 (CURRENT AGORAPHOBIA) CODED YES 
             
                    and 
             
                 IS E7 (CURRENT PANIC DISORDER) CODED YES? 
 
 
 
     NO                     YES 
 
PANIC DISORDER 
with Agoraphobia 
CURRENT 
 
 
  
      IS F2 (CURRENT AGORAPHOBIA) CODED YES 
             
               and 
             
              IS E5 (PANIC DISORDER LIFETIME) CODED NO? 
 
 
 
     NO                     YES 
 
AGORAPHOBIA, CURRENT 
without history of 
Panic Disorder 
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G.  SOCIAL PHOBIA (Social Anxiety Disorder) 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO AND MOVE TO THE NEXT MODULE) 
 
   · 
G1  In the past month, were you fearful or embarrassed being watched, being NO YES  
  the focus of attention, or fearful of being humiliated?  This includes things 
  like speaking in public, eating in public or with others, writing while someone  
  watches, or being in social situations. 
 
 
   · 
G2  Is this social fear excessive or unreasonable? NO YES  
 
   · 
G3  Do you fear these social situations so much that you avoid them or suffer through NO YES  
  them? 
 
  
G4 Do these social fears disrupt your normal work or social functioning or cause you  
  significant distress? 
 
            
SUBTYPES 
 
              Do you fear and avoid 4 or more social situations? 
 
               If YES Generalized social phobia (social anxiety disorder) 
 
               If NO Non-generalized social phobia (social anxiety disorder)  
 
NOTE TO INTERVIEWER: PLEASE ASSESS WHETHER THE SUBJECT’S FEARS ARE 
RESTRICTED TO NON-GENERALIZED (“ONLY 1 OR SEVERAL”) SOCIAL 
SITUATIONS OR EXTEND TO GENERALIZED (“MOST”) SOCIAL SITUATIONS.  
“MOST” SOCIAL SITUATIONS IS USUALLY OPERATIONALIZED TO MEAN 4 OR 
MORE SOCIAL SITUATIONS, ALTHOUGH THE DSM-IV DOES NOT EXPLICITLY 
STATE THIS. 
 
 EXAMPLES OF SUCH SOCIAL SITUATIONSTYPICALLY INCLUDE INITIATING OR 
MAINTAINING A CONVERSATION, PARTICIPATING IN SMALL GROUPS, DATING, 
SPEAKING TO AUTHORITY FIGURES, ATTENDING PARTIES, PUBLIC SPEAKING, 
EATING IN FRONT OF OTHERS, URINATING IN A PUBLIC WASHROOM, ETC.
                                           
     NO                      YES 
 
SOCIAL PHOBIA 
(Social Anxiety Disorder) 
CURRENT 
 
 
GENERALIZED     S 
  
 NON-GENERALIZED    S      
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H.  OBSESSIVE-COMPULSIVE DISORDER 
 
(· MEANS:  GO TO THE DIAGNOSTIC BOX, CIRCLE NO AND MOVE TO THE NEXT MODULE) 
 
    
H1  In the past month, have you been bothered by recurrent thoughts, impulses, or NO YES  
  images that were unwanted, distasteful, inappropriate, intrusive, or distressing? ↓   
  (For example, the idea that you were dirty, contaminated or had germs, or fear of  SKIP TO H4 
  contaminating others, or fear of harming someone even though you didn't want to,  
  or fearing you would act on some impulse, or fear or superstitions that you would  
  be responsible for things going wrong, or obsessions with sexual thoughts, images 
  or impulses, or hoarding, collecting, or religious obsessions.) 
   
  (DO NOT INCLUDE SIMPLY EXCESSIVE WORRIES ABOUT REAL LIFE PROBLEMS.  DO NOT  
  INCLUDE OBSESSIONS DIRECTLY RELATED TO EATING DISORDERS, SEXUAL DEVIATIONS,  
  PATHOLOGICAL GAMBLING, OR ALCOHOL OR DRUG ABUSE BECAUSE THE PATIENT MAY  
  DERIVE PLEASURE FROM THE ACTIVITY AND MAY WANT TO RESIST IT ONLY BECAUSE OF  
  ITS NEGATIVE CONSEQUENCES.) 
 
 
H2  Did they keep coming back into your mind even when you tried to ignore or  NO YES  
  get rid of them? ↓   
   SKIP TO H4 
 
H3  Do you think that these obsessions are the product of your own mind and that NO YES  
  they are not imposed from the outside?  obsessions      
 
 
H4  In the past month, did you do something repeatedly without being able to NO YES  
  resist doing it, like washing or cleaning excessively, counting or checking   compulsions     
  things over and over, or repeating, collecting, arranging things, or other 
  superstitious rituals? 
 
   · 
  IS H3 OR H4 CODED YES? NO YES 
   · 
H5  Did you recognize that either these obsessive thoughts or these  NO YES  
  compulsive behaviors were excessive or unreasonable? 
 
  
H6         Did these obsessive thoughts and/or compulsive behaviors significantly   
              interfere with your normal routine, your work or school, your usual social  
              activities, or relationships, or did they take more than one hour a day? 
                                           
     NO                       YES 
 
O.C.D. 
CURRENT 
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I.  POSTTRAUMATIC STRESS DISORDER (optional) 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
  
   · 
I1  Have you ever experienced or witnessed or had to deal with an extremely traumatic NO YES  
  event that included actual or threatened death or serious injury to you or someone else? 
 
  EXAMPLES OF TRAUMATIC EVENTS INCLUDE: SERIOUS ACCIDENTS, SEXUAL OR PHYSICAL  
  ASSAULT, A TERRORIST ATTACK, BEING HELD HOSTAGE, KIDNAPPING, FIRE, DISCOVERING  
  A BODY, SUDDEN DEATH OF SOMEONE CLOSE TO YOU, WAR, OR NATURAL DISASTER. 
   
   · 
I2  Did you respond with intense fear, helplessness or horror? NO YES  
   
   · 
I3  During the past month, have you re-experienced the event in a distressing way NO YES  
  (such as, dreams, intense recollections, flashbacks or physical reactions)? 
 
 
I4  In the past month: 
 
 a Have you avoided thinking about or talking about the event ? NO YES  
 
 b Have you avoided activities, places or people that remind you of the event? NO YES  
   
 c Have you had trouble recalling some important part of what happened? NO YES  
 
 d Have you become much less interested in hobbies or social activities? NO YES  
 
 e Have you felt detached or estranged from others? NO YES  
 
 f Have you noticed that your feelings are numbed? NO YES  
 
 g Have you felt that your life will be shortened or that you will die sooner than other people? NO YES  
   · 
  ARE 3 OR MORE I4 ANSWERS CODED YES? NO YES 
 
I5  In the past month: 
 
 a Have you had difficulty sleeping? NO YES  
 
 b Were you especially irritable or did you have outbursts of anger? NO YES  
 
 c Have you had difficulty concentrating? NO YES  
 
 d Were you nervous or constantly on your guard? NO YES  
 
 e Were you easily startled? NO YES  
   · 
  ARE 2 OR MORE I5 ANSWERS CODED YES? NO YES 
 
  
  
I6        During the past month, have these problems significantly interfered with 
        your work or social activities, or caused significant distress? 
 
   
 
         
                                          
     NO                      YES 
 
POSTTRAUMATIC 
 STRESS DISORDER 
CURRENT 
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J.  ALCOHOL ABUSE AND DEPENDENCE 
 
(· MEANS:  GO TO DIAGNOSTIC BOXES, CIRCLE NO IN BOTH AND MOVE TO THE NEXT MODULE) 
 
    ·    
J1  In the past 12 months, have you had 3 or more alcoholic drinks within a NO YES  
  3 hour period on 3 or more occasions? 
 
 
J2  In the past 12 months: 
 
 a Did you need to drink more in order to get the same effect that you got when NO YES  
  you first started drinking? 
 
 b When you cut down on drinking did your hands shake, did you sweat or feel agitated?  Did NO YES  
  you drink to avoid these symptoms or to avoid being hungover, for example, "the shakes",  
  sweating or agitation?   
  IF YES TO EITHER, CODE YES. 
 
 c During the times when you drank alcohol, did you end up drinking more than NO YES  
  you planned when you started? 
 
 d Have you tried to reduce or stop drinking alcohol but failed? NO YES  
 
 e On the days that you drank, did you spend substantial time in obtaining NO YES  
  alcohol, drinking, or in recovering from the effects of alcohol? 
 
 f Did you spend less time working, enjoying hobbies, or being with others NO YES  
  because of your drinking? 
 
 g Have you continued to drink even though you knew that the drinking caused NO YES  
  you health or mental problems? 
 
  
            ARE 3 OR MORE J2 ANSWERS CODED YES? 
 
                * IF YES, SKIP J3 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX                            
AND MOVE TO THE NEXT DISORDER.  DEPENDENCE PREEMPTS ABUSE.      
                                       
     NO                      YES* 
 
ALCOHOL DEPENDENCE
CURRENT 
 
J3  In the past 12 months: 
 
 a Have you been intoxicated, high, or hungover more than once when you had other  NO YES  
  responsibilities at school, at work, or at home?  Did this cause any problems?   
  (CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
 b Were you intoxicated more than once in any situation where you were physically at risk, NO YES  
  for example, driving a car, riding a motorbike, using machinery, boating, etc.? 
   
 c Did you have legal problems more than once because of your drinking, for example, NO YES  
  an arrest or disorderly conduct? 
 
 d Did you continue to drink even though your drinking caused problems with your NO YES  
  family or other people? 
  
        
  ARE 1 OR MORE J3 ANSWERS CODED YES? 
 
 
                                              
     NO         N/A         YES 
 
ALCOHOL ABUSE 
CURRENT 
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K.  NON-ALCOHOL PSYCHOACTIVE SUBSTANCE USE DISORDERS 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
   
  Now I am going to show you / read to you a list of street drugs or medicines.  
    ·    
K1 a In the past 12 months, did you take any of these drugs more than once,  NO YES 
  to get high, to feel better, or to change your mood? 
  
 
  CIRCLE EACH DRUG TAKEN: 
  Stimulants:  amphetamines, "speed", crystal meth, “crank”, "rush", Dexedrine, Ritalin, diet pills. 
  Cocaine:  snorting, IV, freebase, crack, "speedball".   
  Narcotics:  heroin, morphine, Dilaudid, opium, Demerol, methadone, codeine, Percodan, Darvon, OxyContin.   
  Hallucinogens:  LSD ("acid"), mescaline, peyote, PCP ("angel dust", "peace pill"), psilocybin, STP, "mushrooms",    
“ecstasy”, MDA, MDMA, or ketamine (“special K”). 
  Inhalants:  "glue", ethyl chloride, “rush”, nitrous oxide ("laughing gas"), amyl or butyl nitrate ("poppers"). 
  Marijuana:  hashish ("hash"), THC, "pot", "grass", "weed", "reefer".   
  Tranquilizers:  Quaalude, Seconal ("reds"), Valium, Xanax, Librium, Ativan, Dalmane, Halcion, barbiturates,                   
Miltown, GHB, Roofinol, “Roofies”.   
  Miscellaneous:  steroids, nonprescription sleep or diet pills.  Any others?  
  SPECIFY MOST USED DRUG(S):     
  
   CHECK ONE BOX  
 ONLY ONE DRUG / DRUG CLASS HAS BEEN USED  
   
 ONLY THE MOST USED DRUG CLASS IS INVESTIGATED.  
   
 EACH DRUG CLASS USED IS EXAMINED SEPARATELY    (PHOTOCOPY K2 AND K3 AS NEEDED)  
 
 b SPECIFY WHICH DRUG/DRUG CLASS WILL BE EXPLORED IN THE INTERVIEW BELOW IF THERE IS 
  CONCURRENT OR SEQUENTIAL POLYSUBSTANCE USE:________________________________________ 
 
K2  Considering your use of (NAME THE DRUG / DRUG CLASS SELECTED), in the past 12 months: 
 
 a Have you found that you needed to use more (NAME OF DRUG / DRUG CLASS SELECTED) NO YES  
   to get the same effect that you did when you first started taking it? 
 
 b When you reduced or stopped using (NAME OF DRUG / DRUG CLASS SELECTED), did you have  NO YES  
  withdrawal symptoms (aches, shaking, fever, weakness, diarrhea, nausea, sweating,  
  heart pounding, difficulty sleeping, or feeling agitated, anxious, irritable, or depressed)? 
  Did you use any drug(s) to keep yourself from getting sick (withdrawal symptoms) or so  
  that you would feel better?   
 
  IF YES TO EITHER, CODE YES. 
 
 c Have you often found that when you used (NAME OF DRUG / DRUG CLASS SELECTED),  NO YES  
  you ended up taking more than you thought you would? 
 
 d Have you tried to reduce or stop taking (NAME OF DRUG / DRUG CLASS SELECTED) but failed? NO YES  
 
 e On the days that you used (NAME OF DRUG / DRUG CLASS SELECTED), did you spend substantial  NO YES  
  time (>2 HOURS), obtaining, using or in recovering from the drug, or thinking about the drug? 
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 f Did you spend less time working, enjoying hobbies, or being with family NO YES  
  or friends because of your drug use? 
 
 g Have you continued to use (NAME OF DRUG / DRUG CLASS SELECTED), even though it caused  NO YES  
  you health or mental problems? 
 
  
              ARE 3 OR MORE K2 ANSWERS CODED YES?   
         
                  SPECIFY DRUG(S): __________________________________ 
  
* IF YES, SKIP K3 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX FOR THIS 
SUBSTANCE AND MOVE TO THE NEXT DISORDER.   
DEPENDENCE PREEMPTS ABUSE.  
     
 
     NO                      YES *
 
SUBSTANCE DEPENDENCE 
CURRENT 
 
 
 
  Considering your use of (NAME THE DRUG CLASS SELECTED), in the past 12 months: 
 
K3 a Have you been intoxicated, high, or hungover from (NAME OF DRUG / DRUG CLASS SELECTED)  NO YES  
  more than once, when you had other responsibilities at school, at work, or at home?   
  Did this cause any problem? 
   
  (CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
 b Have you been high or intoxicated from (NAME OF DRUG / DRUG CLASS SELECTED) NO YES  
  more than once in any situation where you were physically at risk (for example,  
  driving a car, riding a motorbike, using machinery, boating, etc.)? 
 
 c Did you have legal problems more than once because of your drug use, for example, NO YES  
  an arrest or disorderly conduct? 
 
 d Did you continue to use (NAME OF DRUG /  DRUG CLASS SELECTED), even though it caused  NO YES  
  problems with your family or other people? 
 
  
       ARE 1 OR MORE K3 ANSWERS CODED YES? 
 
             SPECIFY DRUG(S): __________________________________ 
            
                                              
     NO        N/A       YES 
 
SUBSTANCE ABUSE 
CURRENT 
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L. PSYCHOTIC DISORDERS AND MOOD DISORDER WITH PSYCHOTIC 
FEATURES 
 
ASK FOR AN EXAMPLE OF EACH QUESTION ANSWERED POSITIVELY.  CODE YES ONLY IF THE EXAMPLES CLEARLY SHOW A DISTORTION OF THOUGHT OR OF 
PERCEPTION OR IF THEY ARE NOT CULTURALLY APPROPRIATE.  BEFORE CODING, INVESTIGATE WHETHER DELUSIONS QUALIFY AS "BIZARRE". 
 
DELUSIONS ARE "BIZARRE" IF: CLEARLY IMPLAUSIBLE, ABSURD, NOT UNDERSTANDABLE, AND CANNOT DERIVE FROM ORDINARY LIFE EXPERIENCE. 
 
HALLUCINATIONS ARE SCORED "BIZARRE" IF: A VOICE COMMENTS ON THE PERSON'S THOUGHTS OR BEHAVIOR, OR WHEN TWO OR MORE VOICES ARE 
CONVERSING WITH EACH OTHER. 
 
  Now I am going to ask you about unusual experiences that some people have.  BIZARRE  
      
L1 a Have you ever believed that people were spying on you, or that someone NO YES YES   
  was plotting against you, or trying to hurt you?     
  NOTE:  ASK FOR EXAMPLES TO RULE OUT ACTUAL STALKING.     
       
 b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES   
     ·L6  
        
L2 a Have you ever believed that someone was reading your mind or could hear NO YES YES   
  your thoughts, or that you could actually read someone’s mind or hear what      
  another person was thinking?      
        
 b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES   
     ·L6   
       
L3 a Have you ever believed that someone or some force outside of yourself  NO YES YES   
  put thoughts in your mind that were not your own, or made you act in a     
  way that was not your usual self?  Have you ever felt that you were     
  possessed?     
  CLINICIAN:  ASK FOR EXAMPLES AND DISCOUNT ANY THAT ARE NOT PSYCHOTIC.     
       
 b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES   
     ·L6   
        
L4 a Have you ever believed that you were being sent special messages through NO YES YES   
  the TV, radio, or newspaper, or that a person you did not personally know     
  was particularly interested in you?      
       
 b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES   
     ·L6  
       
L5 a Have your relatives or friends ever considered any of your beliefs strange NO YES YES   
  or unusual?     
  INTERVIEWER: ASK FOR EXAMPLES. ONLY CODE YES IF THE EXAMPLES ARE CLEARLY      
  DELUSIONAL IDEAS NOT EXPLORED IN QUESTIONS L1 TO L4, FOR EXAMPLE, SOMATIC OR RELIGIOUS      
  DELUSIONS OR DELUSIONS OF GRANDIOSITY, JEALOUSY, GUILT, RUIN OR DESTITIUTION, ETC.     
       
 b IF YES OR YES BIZARRE: do they currently consider your beliefs strange? NO YES YES   
       
L6 a Have you ever heard things other people couldn't hear, such as voices? NO YES    
  HALLUCINATIONS ARE SCORED "BIZARRE" ONLY IF PATIENT ANSWERS YES TO THE FOLLOWING:     
       
  IF YES: Did you hear a voice commenting on your thoughts or behavior or NO    YES  
  did you hear two or more voices talking to each other?     
       
 b IF YES OR YES BIZARRE TO L6a: have you heard these things in the past month?  NO YES YES   
  HALLUCINATIONS ARE SCORED "BIZARRE" ONLY IF PATIENT ANSWERS YES TO THE FOLLOWING:   ·L8b  
  Did you hear a voice commenting on your thoughts or behavior or 
  did you hear two or more voices talking to each other? 
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L7 a Have you ever had visions when you were awake or have you ever seen things  NO YES  
  other people couldn't see?  
  CLINICIAN: CHECK TO SEE IF THESE ARE CULTURALLY INAPPROPRIATE. 
 
 b IF YES:  have you seen these things in the past month? NO YES  
 
  CLINICIAN'S JUDGMENT 
 
L8 b IS THE PATIENT CURRENTLY EXHIBITING INCOHERENCE, DISORGANIZED  NO YES  
  SPEECH, OR MARKED LOOSENING OF ASSOCIATIONS? 
 
L9 b IS THE PATIENT CURRENTLY EXHIBITING DISORGANIZED OR CATATONIC  NO YES  
  BEHAVIOR? 
 
L10 b ARE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA, E.G. SIGNIFICANT AFFECTIVE  NO YES  
  FLATTENING, POVERTY OF SPEECH (ALOGIA) OR AN INABILITY TO INITIATE   
  OR PERSIST IN GOAL-DIRECTED ACTIVITIES (AVOLITION), PROMINENT DURING  
  THE INTERVIEW? 
 
L11 a ARE 1 OR MORE « a » QUESTIONS FROM L1a TO L7a CODED YES OR YES BIZARRE  
  AND IS EITHER: 
  
   MAJOR DEPRESSIVE EPISODE, (CURRENT OR RECURRENT) 
   OR  
    MANIC OR HYPOMANIC EPISODE, (CURRENT OR PAST) CODED YES? NO YES 
   ·L13 
  IF NO TO L11 a, CIRCLE NO IN BOTH ‘MOOD DISORDER WITH PSYCHOTIC  
  FEATURES’ DIAGNOSTIC BOXES AND MOVE TO L13. 
 
  
        b   You told me earlier that you had period(s) when you felt (depressed/high/persistently  
            irritable). 
 
           Were the beliefs and experiences you just described (SYMPTOMS CODED YES FROM L1a TO L7a) 
                  restricted exclusively to times when you were feeling depressed/high/irritable?   
                
             IF THE PATIENT EVER HAD A PERIOD OF AT LEAST 2 WEEKS OF HAVING THESE 
BELIEFS OR EXPERIENCES (PSYCHOTIC SYMPTOMS) WHEN THEY WERE NOT 
DEPRESSED/HIGH/IRRITABLE, CODE NO TO THIS DISORDER.  
 
            IF THE ANSWER IS NO TO THIS DISORDER, ALSO CIRCLE NO TO L12 AND MOVE TO L13 
               
                                  
     NO                     YES 
 
 
MOOD DISORDER WITH 
PSYCHOTIC FEATURES 
 
LIFETIME 
 
 
  
L12 a ARE 1 OR MORE « b » QUESTIONS FROM L1b TO L7b CODED YES OR YES BIZARRE 
AND IS EITHER: 
  
   MAJOR DEPRESSIVE EPISODE, (CURRENT) 
   OR 
    MANIC OR HYPOMANIC EPISODE, (CURRENT) CODED YES? 
 
 
IF THE ANSWER IS YES TO THIS DISORDER (LIFETIME OR CURRENT),                      
CIRCLE NO TO L13 AND L14 AND MOVE TO THE NEXT MODULE. 
 
                                        
     NO                     YES 
 
 
MOOD DISORDER WITH 
PSYCHOTIC FEATURES 
 
CURRENT 
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 L13      ARE 1 OR MORE « b » QUESTIONS FROM L1b TO L6b, CODED YES BIZARRE? 
             
                OR 
 
               ARE 2 OR MORE « b » QUESTIONS FROM L1b TO L10b, CODED YES (RATHER      
THAN YES BIZARRE)? 
   
AND DID AT LEAST TWO OF THE PSYCHOTIC SYMPTOMS OCCUR DURING THE 
SAME 1 MONTH PERIOD? 
 
                                              
     NO                       YES 
 
PSYCHOTIC DISORDER 
CURRENT 
 
 
 
  
 L14     IS L13 CODED YES  
 
                 OR  
 
                 ARE 1 OR MORE « a » QUESTIONS FROM L1a TO L6a, CODED YES BIZARRE?             
             
              OR 
 
            ARE 2 OR MORE « a » QUESTIONS  FROM L1a TO L7a, CODED YES (RATHER THAN  
YES BIZARRE) 
   
             AND DID AT LEAST TWO OF THE PSYCHOTIC SYMPTOMS OCCUR DURING THE  
SAME 1 MONTH PERIOD? 
 
                                          
     NO                      YES 
 
 
 
PSYCHOTIC DISORDER 
LIFETIME 
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M.  ANOREXIA NERVOSA  
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
M1 a How tall are you? Rft RRin. 
   R R Rcm.          
 b.  What was your lowest weight in the past 3 months? R R Rlbs. 
   R R Rkgs.  
   ·   
 c IS PATIENT’S WEIGHT EQUAL TO OR BELOW THE THRESHOLD CORRESPONDING TO NO YES   
  HIS / HER HEIGHT?  (SEE TABLE BELOW)    
   
  In the past 3 months: 
   · 
M2  In spite of this low weight, have you tried not to gain weight? NO YES  
   · 
M3  Have you intensely feared gaining weight or becoming fat, even though you were underweight? NO YES  
 
M4 a Have you considered yourself too big / fat or that part of your body was too big / fat? NO YES  
 
 b Has your body weight or shape greatly influenced how you felt about yourself? NO YES  
 
 c Have you thought that your current low body weight was normal or excessive? NO YES  
   · 
M5  ARE 1 OR MORE ITEMS FROM M4 CODED YES? NO YES 
   · 
M6  FOR WOMEN ONLY:  During the last 3 months, did you miss all your menstrual NO YES  
  periods when they were expected to occur (when you were not pregnant)? 
 
  
         
            FOR WOMEN:         ARE M5 AND M6 CODED YES? 
             
              FOR MEN:               IS M5 CODED YES? 
   
 
            
                                              
     NO                      YES 
 
ANOREXIA NERVOSA 
CURRENT 
 
HEIGHT / WEIGHT TABLE CORRESPONDING TO A BMI THRESHOLD OF 17.5 KG/M2  
 
Height/Weight 
ft/in 4'9 4'10 4'11 5'0 5'1 5'2 5'3 5'4 5'5 5'6 5'7 5'8 5'9 5'10 
lbs. 81 84 87 89 92 96 99 102 105 108 112 115 118 122 
cm 145 147 150 152 155 158 160 163 165 168 170 173 175 178 
kgs 37 38 39 41 42 43 45 46 48 49 51 52 54 55 
     
Height/Weight  
ft/in 5'11 6'0 6'1 6'2 6'3  
lbs. 125 129 132 136 140  
cm 180 183 185 188 191  
kgs 57 59 60 62 64 
The weight thresholds above are calculated using a body mass index (BMI) equal to or below 17.5 kg/m2 for the patient's height.  This 
is the threshold guideline below which a person is deemed underweight by the DSM-IV and the ICD-10 Diagnostic Criteria for 
Research for Anorexia Nervosa. 
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N.  BULIMIA NERVOSA 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
   · 
N1  In the past three months, did you have eating binges or times when you ate  NO YES  
  a very large amount of food within a 2-hour period?  
   · 
N2  In the last 3 months, did you have eating binges as often as twice a week? NO YES  
 
   · 
N3  During these binges, did you feel that your eating was out of control? NO YES  
   · 
N4  Did you do anything to compensate for, or to prevent a weight gain from these   NO YES  
  binges, like vomiting, fasting, exercising or taking laxatives, enemas, diuretics  
  (fluid pills), or other medications? 
   · 
N5  Does your body weight or shape greatly influence how you feel about yourself? NO YES  
 
N6  DO THE PATIENT’S SYMPTOMS MEET CRITERIA FOR ANOREXIA NERVOSA? NO YES  
   ↓ 
   Skip to N8 
  
N7  Do these binges occur only when you are under (          lbs./kgs.)? NO YES  
  INTERVIEWER: WRITE IN THE ABOVE PARENTHESIS THE THRESHOLD WEIGHT FOR THIS PATIENT’S  
  HEIGHT FROM THE HEIGHT / WEIGHT TABLE IN THE ANOREXIA NERVOSA MODULE.  
  
             
 N8       IS N5 CODED YES AND IS EITHER N6 OR N7 CODED NO?  
 
            
                                              
     NO                      YES 
 
BULIMIA NERVOSA 
CURRENT 
 
 
   
               IS N7 CODED YES? 
 
         
   
 
            
                                              
     NO                      YES 
 
ANOREXIA NERVOSA 
Binge Eating/Purging Type
CURRENT 
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O.  GENERALIZED ANXIETY DISORDER 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
   · 
O1 a  Have you worried excessively or been anxious about several things NO YES  
   over the past 6 months?   
    · 
 b  Are these worries present most days? NO YES  
     · 
   IS THE PATIENT’S ANXIETY RESTRICTED EXCLUSIVELY  NO YES  
   TO, OR BETTER EXPLAINED BY, ANY DISORDER PRIOR TO THIS POINT? 
 
    · 
O2   Do you find it difficult to control the worries or do they interfere with NO YES  
   your ability to focus on what you are doing? 
 
O3   FOR THE FOLLOWING, CODE NO IF THE SYMPTOMS ARE CONFINED TO  
   FEATURES OF ANY DISORDER EXPLORED PRIOR TO THIS POINT. 
    
   When you were anxious over the past 6 months, did you, most of the time:   
 
  a Feel restless, keyed up or on edge? NO YES  
 
  b Feel tense? NO YES  
 
  c Feel tired, weak or exhausted easily? NO YES  
 
  d Have difficulty concentrating or find your mind going blank? NO YES  
 
  e Feel irritable? NO YES  
 
  f Have difficulty sleeping (difficulty falling asleep, waking up in the middle NO YES  
   of the night, early morning wakening or sleeping excessively)? 
 
  
      ARE 3 OR MORE O3 ANSWERS CODED YES? 
 
 
            
                                           
     NO                       YES 
 
GENERALIZED 
ANXIETY DISORDER 
CURRENT 
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P. ANTISOCIAL PERSONALITY DISORDER (optional) 
 
(· MEANS :  GO TO THE DIAGNOSTIC BOX AND CIRCLE NO.) 
 
P1  Before you were 15 years old, did you: 
 
 a  repeatedly skip school or run away from home overnight? NO YES  
 
 b  repeatedly lie, cheat, "con" others, or steal? NO YES  
 
 c  start fights or bully, threaten, or intimidate others? NO YES  
 
 d  deliberately destroy things or start fires? NO YES  
 
 e  deliberately hurt animals or people? NO YES  
 
 f  force someone to have sex with you? NO YES  
   · 
  ARE 2 OR MORE P1 ANSWERS CODED YES? NO YES  
 
  DO NOT CODE YES TO THE BEHAVIORS BELOW IF THEY ARE EXCLUSIVELY  
  POLITICALLY OR RELIGIOUSLY MOTIVATED. 
 
P2  Since you were 15 years old, have you: 
 
 a repeatedly behaved in a way that others would consider irresponsible, like NO YES  
  failing to pay for things you owed, deliberately being impulsive or deliberately 
  not working to support yourself?   
 
 b done things that are illegal even if you didn't get caught (for example, destroying NO YES  
  property, shoplifting, stealing, selling drugs, or committing a felony)? 
 
 c been in physical fights repeatedly (including physical fights with your NO YES  
  spouse or children)? 
 
 d often lied or "conned" other people to get money or pleasure, or lied just  NO YES  
  for fun? 
 
 e exposed others to danger without caring? NO YES  
 
 f felt no guilt after hurting, mistreating, lying to, or stealing from others, or NO YES  
  after damaging property? 
 
   
 
  ARE 3 OR MORE P2 QUESTIONS CODED YES? 
 
 
         
   
 
                                                    
    NO                              YES 
 
ANTISOCIAL PERSONALITY 
DISORDER 
LIFETIME 
 
 
THIS CONCLUDES THE INTERVIEW
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GOKULASANKARAN 23 M S 9TH UNSKIL URBAN LOWERHINDU 14 9 YES YES NO YES YES YES YES YE YES YES YES YES 2 1 1 1 1 40 PSYCHOSIS 29
NAWAB SULTHAN 31 M M 9TH 0 RURAL LOWERISLAM 5 26 YES YES YES YES YES YE YES YES 2 2 2 1 2 16 PSYCHOSIS 40
MUNUSAMY 22 M S 8TH 0 URBAN LOWERHINDU 10 12 YES YES YES YES YES YES YE YES YES YES 2 2 2 1 2 36 MANIA 6
AJITHKUMAR 19 M S 6TH 0 URBAN LOWERCHRISTIAN 12 7 YES YES YES YES YES YES YES 2 1 1 1 1 24 PSYCHOSIS 1
ARULKUMAR 22 M S 9TH 0 URBAN LOWERHINDU 7 15 YES YES YES YES YES YES FEVIBOND YES 2 1 2 1 2 30 PSYCHOSIS 5
DHARMARAJ 23 M S 10TH UNSKIL URBAN LOWERHINDU 20 3 YE YES YES YES 1 1 1 1 1 8 PSYCHOSIS 6
SILAMBARASAN 30 M S 6TH SEMISKURBAN LOWERHINDU 29 1 YES YES 1 1 1 1 1 0 PSYCHOSIS 6
MARUSAMY 35 M S 2ND SEMISKRURAL LOWERHINDU 15 20 YES YES YES YES YES YES YES 2 1 1 1 2 24 MANIA 0.5
ANANDRAJ 25 M S 10TH UNSKIL RURAL LOWERHINDU 15 10 YES YES NITRAZEPAM YES 1 1 1 1 1 18 DEPRESSIO 18
PRAKASH 20 M S 10TH UNSKIL URBAN LOWERHINDU 14 6 YES YES 2 1 1 1 2 20 PSYCHOSIS 7
SARANRAJ 23 M S DEGREE 0 URBAN LOWERHINDU 21 2 YES YES YES YES YES 1 1 1 1 1 0 PSYCHOSIS 1
PRASHANTH 21 M S 12TH SKILLEDURBAN LOWERHINDU 14 7 YES YES YES YES YES YES 2 1 1 1 2 18 L 6
SARANRAJ 21 M S 9TH SEMISKURBAN LOWERHINDU 15 6 YES YES YES YES YES YE YES TURPENTINE OIL YES 2 1 1 1 2 42 PSYCHOSIS 3
CHANDRAKANTHAN 25 M S DEGREE 0 RURAL LOWERHINDU 20 1 YES YES YES YES YE YES YES YES 1 1 1 1 1 8 PSYCHOSIS 36
RAMESH 20 M S DEGREE 0 URBAN LOWERHINDU 17 3 YES YES YES YES YE YES 1 1 1 1 1 8 ASPD 36
BALAJI 20 M S DEGREE 0 URBAN LOWERHINDU 17 3 YES YES YES YES YES NIT, SPASM, SOLVENTS 1 1 1 1 1 8 ASPD 24
THANGADURAI 19 M S 9TH SKILLEDURBAN LOWERHINDU 12 7 YES YES YES YES YES 2 1 1 1 2 12 PSYCHOSIS 10
SIVA 18 M S 5TH 0 URBAN LOWERHINDU 16 3 YES YES YES YES YES YES YES YES YES FEVIBOND YES 1 1 1 1 1 12 ASPD 12
SURYA 17 M S 8TH 0 URBAN LOWERHINDU 16 1 YES YES YES YES YES YES 1 1 1 2 1 14 L 12
BARNABAS 31 M M 10TH UNSKIL URBAN LOWERCHRISTIAN 28 3 YES YES YES YE YES HANS YES 1 2 2 1 1 12 PSYCHOSIS 6
KANDHAN 28 M S 6TH SEMISKURBAN LOWERHINDU 21 7 YES YES YES 2 1 1 1 2 14 PSYCHOSIS 36
VIGNESH 18 M S 9th UNSKIL URBAN LOWERHINDU 15 13 YES YES YES 3 1 1 1 3 24 MANIA 1
VALLARASU 25 M S 10TH 0 RURAL LOWERHINDU 15 10 YES YES YES YES YES YES YES YES 2 1 1 1 2 26 PSYCHOSIS 36
EDWIN 21 M S 8TH SEMISKURBAN LOWERCHRISTIAN 17 4 YES YES YES YES YE YES NITRAZEPAM YES 1 1 1 1 1 0 L 24
PRASATH 18 M S 10TH 0 URBAN LOWERCHRISTIAN 15 3 YES YES YES YES YES YE YES YES 1 1 1 1 1 12 ASPD 18
ELUMALAI 19 M S 8TH SEMISKURBAN LOWERHINDU 16 3 YES YES YES YES 1 1 1 1 1 8 PSYCHOSIS 14
PALANI 38 M M 6TH UNSKIL URBAN LOWERHINDU 18 20 YES YES YES YES YE YES YES 3 1 1 1 3 32 PSYCHOSIS 60
SELVAKUMAR 27 M S 8TH SKILLEDRURAL LOWERHINDU 16 11 YES YES YES YES 2 1 1 1 2 24 MANIA 3
VINOTHKUMAR 19 M S 10TH SKILLEDURBAN LOWERHINDU 15 4 YES YES YES YE YES YES MAWA YES 1 1 1 1 1 22 ASPD 18
MUTHU 36 M S 4TH SKILLEDURBAN LOWERHINDU 16 20 YES YES YES YES YES YES YE YES YES 2 1 1 1 2 14 L 6
SRINIVASAN 38 M M 4TH SKILLEDURBAN LOWERHINDU 34 4 YES YE YES YES HANS, MAWA YES 1 1 1 1 1 18 PSYCHOSIS 6
VIGNESH 22 M S 5TH 0 URBAN LOWERHINDU 19 3 YES YES YES YES YE YES YES 1 1 1 1 1 8 L 12
ABDULGANI 27 M M 3RD SKILLEDURBAN LOWERISLAM 23 4 YES HANS, MAWA 1 1 1 1 1 8 PSYCHOSIS 24
VENKATESAN 25 M S 3RD UNSKIL URBAN LOWERHINDU 13 12 YES YE YES YES COUGH SYP YES 2 1 1 1 2 18 PSYCHOSIS 1
RAJKAMAL 28 M S 10TH 0 URBAN LOWERHINDU 20 8 YES YES YES YES 1 1 1 1 1 12 L 36
GANESAN 32 M DI 3RD SKILLEDURBAN LOWERHINDU 19 13 YES YES YES YES YES YES 2 1 1 1 2 20 L 3
KRISHNAMURTHY 42 M M 9TH UNSKIL URBAN LOWERHINDU 18 24 YES YE YES YES 2 1 1 1 2 24 L 6
KOTTAISAMY 33 M S 12TH SKILLEDURBAN MIDDL HINDU 18 15 YES YES YES YES YE YES MAWA YES 1 1 1 1 1 24 PSYCHOSIS 40
VINODHKUMAR 25 M S 10TH SKILLEDRURAL LOWERHINDU 15 10 YES YES YES YES YES YES 1 1 1 1 1 28 PSYCHOSIS 36
RAMESH 27 M S 5TH SEMISKURBAN LOWERHINDU 12 15 YES YES YES YES 2 1 1 1 2 30 PSYCHOSIS 60
KARTHIK 20 M S 9TH 0 RURAL LOWERHINDU 17 3 YES YES YES YES YES YES YES YES YES 1 1 1 1 1 10 PSYCHOSIS 6
SANKAR 32 M M 8TH SKILLEDRURAL LOWERHINDU 20 12 YES YES YES YES YES HANS YES 2 1 1 1 2 24 MANIA 2
MADANKUMAR 29 M M 9TH SKILLEDURBAN LOWERHINDU 25 4 YES YES YES YES YES YE YES FEVIBOND YES 1 1 1 1 1 18 L 18
VENKATESH 28 M S 12TH SKILLEDURBAN LOWERHINDU 18 10 YES YE YES YES HANS YES 2 1 1 1 2 24 PSYCHOSIS 60
BALAJI 19 M S DEGREE 0 URBAN LOWERHINDU 16 3 YES YES YE YES YES 1 1 1 1 1 12 MANIA 1
NAGESWARAN 32 M S 2ND UNSKIL URBAN LOWERHINDU 29 3 YES YES YES 1 1 1 1 1 0 PSYCHOSIS 32
STEPHENRAJ 22 M S DIPLOMA UNSKIL URBAN MIDDL HINDU 19 3 YES YES YES 1 1 1 1 1 0 MANIA 1
SARAVANAN 30 M M 10TH SEMISKURBAN LOWERHINDU 24 6 YES YE YES YES 1 1 1 1 1 8 PSYCHOSIS 28
KARTHIK 25 M S ITI 0 URBAN LOWERCHRISTIAN 17 8 YES YES YES YE YES YES FEVIBOND YES 1 1 1 1 1 12 L 14
ARAVINDHAN 20 M S 10TH 0 RURAL LOWERHINDU 8 12 YES YES YES YES YE YES 1 1 1 2 1 18 PSYCHOSIS 60
SATHISHKUMAR 21 M S 7TH UNSKIL RURAL LOWERHINDU 17 4 YES YES 1 2 2 1 1 8 PSYCHOSIS 12
NAGARAJ 30 M M ITI UNSKIL URBAN LOWERHINDU 25 5 YES YES NITRAZEPYES 1 1 1 1 1 24 MANIA 2
SARAVANAN 28 M S DEGREE SEMISKRURAL LOWERHINDU 25 3 YES YES YES 1 1 1 1 1 12 PSYCHOSIS 48
VETRI 30 M S 5TH UNSKIL SEMI LOWERHINDU 27 3 YES YES YE YES YES YES 1 1 1 1 1 8 PSYCHOSIS 12
JEEVA 25 M S DIPLOMA SKILLEDURBAN LOWERHINDU 19 6 YES YES YE YES YES 2 1 1 1 2 8 PSYCHOSIS 32
PRAKASH 32 M S 5TH SKILLEDSEMI LOWERHINDU 30 2 YES YES YES YE YES YES 0 1 1 1 0 8 L 8
SIVANATHAN 49 M M 7TH UNSKIL RURAL LOWERHINDU 15 24 YES YES YES YES YES YES 3 1 1 1 3 24 PSYCHOSIS 120
RAVIKUMAR 48 M M 10TH SKILLEDURBAN LOWERHINDU 30 18 YES 2 1 1 1 2 22 PSYCHOSIS 24
KISHOREKUMAR 23 M S 9TH 0 URBAN LOWERHINDU 17 6 YES YES YES YES YE YES YES YES YES 1 1 1 1 1 12 ASPD 48
PRABU 33 M S 6TH 0 RURAL LOWERHINDU 25 8 YES YES YES YES YES 1 1 1 1 1 14 PSYCHOSIS 72
SANKAR 27 M S DIPLOMA 0 RURAL LOWERHINDU 23 4 YES YES YES YES 1 1 1 1 1 22 PSYCHOSIS 6
NAGARAJ 23 M S 7TH SKILLEDURBAN LOWERHINDU 19 4 YES YES YES YES 1 1 1 1 1 18 PSYCHOSIS 24
PRASANTH 21 M S 12TH SEMISKURBAN LOWERHINDU 18 3 YES YES YE YES YES YES 1 1 1 1 1 4 PSYCHOSIS 18
SIVACHANDRAN 27 M S ITI 0 RURAL LOWERHINDU 20 7 YES YES YES YES YES YES 2 1 1 1 2 14 PSYCHOSIS 36
PRAKASH 25 M S 9TH 0 URBAN LOWERHINDU 17 8 YES YES YES YES YES 1 1 1 1 1 18 PSYCHOSIS 24
GUBENDRAN 29 M M DEGREE UNSKIL RURAL LOWERHINDU 24 5 0 YES 1 1 1 1 1 18 PSYCHOSIS 18
JEYARAJ 35 M M 10TH 0 URBAN LOWERCHRISTIAN 20 15 YES YES YES YES 2 1 1 2 2 24 PSYCHOSIS 30
VIJITH 21 M S ITI 0 URBAN LOWERHINDU 17 4 YES YES YES YES YES 0 YE YES YES NITRAZEPAM YES 1 2 2 1 1 8 L 12
MALAKONDAIYYA 43 M M 0 SEMISKURBAN MIDDL HINDU 23 20 YES 2 1 1 1 2 8 PSYCHOSIS 120
DEVARAJ 17 M S 9TH UNSKIL URBAN LOWERHINDU 13 4 YES YES YES YES YES 0 YES YES YES 1 1 1 1 1 8 PSYCHOSIS 8
VENKATESAN 26 M M 8TH SKILLEDSEMI LOWERHINDU 21 5 YES YES YES 1 1 1 1 1 8 MANIA 3
PARTHIBAN 18 M S 10TH 0 SEMI LOWERHINDU 15 3 YES YES YES YES YES YE YES FEVIBOND YES 1 1 1 1 1 8 MANIA 2
MURUGA 19 M S DEGREE 0 URBAN LOWERHINDU 17 2 YES YES YES 0 HANS YES 1 1 1 1 1 8 PSYCHOSIS 12
PARTHASARATHI 21 M S 10TH 0 URBAN LOWERHINDU 19 2 YES YES YES YES YES YES 1 1 1 1 1 8 PSYCHOSIS 6
VIJAYAKUMAR 17 M S 9TH SKILLEDURBAN LOWERHINDU 15 2 YES YES 0 1 1 1 1 1 8 L 0.5
SARAVANAN 24 M S 8TH 0 URBAN LOWERHINDU 16 8 YES 0 YES YES YES YES 1 1 1 1 1 PSYCHOSIS 18
MADHAN 18 M S 6TH 0 SEMI LOWERHINDU 16 2 YES YES YES YES FEVIBOND YES 1 1 1 1 1 0 PSYCHOSIS 3
GOPALAKRISHNAN 45 M DI 3RD SEMISKURBAN LOWERHINDU 25 20 YES YE YES YES 2 1 1 1 2 18 PSYCHOSIS 84
JHONY 21 M S ITI UNSKIL URBAN LOWERCHRISTIAN 16 5 YES YES YES NITRAZEPAM YES 2 1 1 1 2 8 PSYCHOSIS 12
MICHAELRAJ 27 M DI 6TH SKILLEDURBAN LOWERHINDU 19 8 YES YES 1 1 1 1 1 8 PSYCHOSIS 6
MARIMUTHU 25 M M 3RD UNSKIL URBAN LOWERHINDU 18 7 YES YES 0 YE YES YES MAVA, HANS YES 1 1 1 1 1 8 PSYCHOSIS 24
RAJKUMAR 20 M S 8TH 0 RURAL LOWERHINDU 14 6 YES YES YES YES 0 1 1 1 1 1 8 PSYCHOSIS 12
MANIKANDAN 20 M S 7TH UNSKIL URBAN LOWERHINDU 16 4 YES YES 0 YES YES YES 1 1 1 1 1 8 PSYCHOSIS 6
SAMEER 33 M M 0 0 SEMI LOWERISLAM 30 3 YES YES YES YES YES 1 1 1 1 1 8 PSYCHOSIS 36
GUNASEGARAN 35 M S 6TH 0 RURAL LOWERHINDU 30 5 YES YES YES YES YES 1 1 1 1 1 18 PSYCHOSIS 12
MAGESH 21 M S 7TH 0 URBAN LOWERHINDU 16 5 YES YES YES 0 YES HANS YES 1 1 1 1 1 8 L 24
SUKUMAR 18 M S 8TH 0 SEMI MIDDL HINDU 10 8 YES YES YES 0 YES 1 1 1 1 1 12 L 18
RAMKUMAR 19 M S 7TH UNSKIL URBAN LOWERHINDU 15 4 YES YES 0 YES YES 1 1 1 1 1 18 PSYCHOSIS 6
SURESH 24 M M 7TH SKILLEDURBAN LOWERHINDU 17 7 YES YES YES YE YES YES 1 1 1 1 1 24 L 24
NITHISH 22 M S 8TH UNSKIL URBAN LOWERHINDU 16 6 YES HANS YES 1 1 1 1 1 8 L 20
RAJESH 24 M S 9TH UNSKIL URBAN LOWERHINDU 20 4 YES YE YES YES YES 1 1 1 1 1 14 PSYCHOSIS 3
VIJAYAKUMAR 18 M S ITI 0 URBAN LOWERHINDU 15 3 YES YES 1 1 1 1 1 0 MANIA 2
NOORULLAH 26 M S 8TH UNSKIL URBAN LOWERISLAM 22 4 YES YES YES YES YE YES HANS YES 1 1 1 1 1 14 PSYCHOSIS 12
ELUMALAI 21 M S 6TH SKILLEDSEMI LOWERHINDU 18 3 YES YES YES YES 1 1 1 1 1 8 PSYCHOSIS 6
DURAI 20 M S 7TH UNSKIL URBAN LOWERHINDU 16 4 YES YES YE YES YES YES 1 1 1 1 1 12 PSYCHOSIS 5
BABU 19 M S 4TH UNSKIL SEMI LOWERHINDU 16 3 YES YE YES YES 1 1 1 1 1 8 L 12
SUDHAKAR 24 M S 6TH UNSKIL RURAL LOWERHINDU 20 4 YES YES YES YES MAVA 1 1 1 1 1 4 L 20
JOHN 28 M M 6TH SEMISKRURAL LOWERCHRISTIAN 24 4 YES YES YES YES 1 1 1 1 1 8 PSYCHOSIS 8
BASKAR 21 M S 9TH SKILLEDURBAN LOWERHINDU 17 4 YES YES YES YES YES 1 1 1 1 1 0 L 12
DINESH 23 M S 10TH SKILLEDURBAN LOWERHINDU 18 5 YES YES YES YES YES 1 1 0 1 1 8 L 36
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